201
|
In silico mutational analysis of ACE2 to check the susceptibility of lung cancer patients towards COVID-19. Sci Rep 2022; 12:7798. [PMID: 35552474 PMCID: PMC9098448 DOI: 10.1038/s41598-022-11805-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Accepted: 04/25/2022] [Indexed: 11/24/2022] Open
Abstract
Being the second major cause of death worldwide, lung cancer poses a significant threat to the health of patients. This worsened during the era of pandemic since lung cancer is found to be more prone to SARS-CoV-2 infection. Many recent studies imply a high frequency of COVID-19 infection associated severe outcome. However, molecular studies are still lacking in this respect. Hence the current study is designed to investigate the binding affinities of ACE2 lung cancer mutants with the viral spike protein to find the susceptibility of respective mutants carrying patients in catching the virus. Quite interestingly, our study found lesser binding affinities of all the selected mutants thus implying that these cancer patients might be less affected by the virus than others. These results are opposed to the recent studies’ propositions and open new avenues for more in-depth studies.
Collapse
|
202
|
Degarege A, Naveed Z, Kabayundo J, Brett-Major D. Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis. Pathogens 2022; 11:563. [PMID: 35631084 PMCID: PMC9147100 DOI: 10.3390/pathogens11050563] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2022] [Revised: 05/02/2022] [Accepted: 05/05/2022] [Indexed: 02/07/2023] Open
Abstract
This systematic review and meta-analysis synthesized the evidence on the impacts of demographics and comorbidities on the clinical outcomes of COVID-19, as well as the sources of the heterogeneity and publication bias of the relevant studies. Two authors independently searched the literature from PubMed, Embase, Cochrane library, and CINAHL on 18 May 2021; removed duplicates; screened the titles, abstracts, and full texts by using criteria; and extracted data from the eligible articles. The variations among the studies were examined by using Cochrane, Q.; I2, and meta-regression. Out of 11,975 articles that were obtained from the databases and screened, 559 studies were abstracted, and then, where appropriate, were analyzed by meta-analysis (n = 542). COVID-19-related severe illness, admission to the ICU, and death were significantly correlated with comorbidities, male sex, and an age older than 60 or 65 years, although high heterogeneity was present in the pooled estimates. The study design, the study country, the sample size, and the year of publication contributed to this. There was publication bias among the studies that compared the odds of COVID-19-related deaths, severe illness, and admission to the ICU on the basis of the comorbidity status. While an older age and chronic diseases were shown to increase the risk of developing severe illness, admission to the ICU, and death among the COVID-19 patients in our analysis, a marked heterogeneity was present when linking the specific risks with the outcomes.
Collapse
Affiliation(s)
- Abraham Degarege
- Department of Epidemiology, College of Public Health, University of Nebraska Medical Center, Omaha, NE 68198, USA; (Z.N.); (J.K.); (D.B.-M.)
| | | | | | | |
Collapse
|
203
|
Chiruvella V, Ullah A, Elhelf I, Patel N, Karim NA. Would the Addition of Immunotherapy Impact the Prognosis of Patients With Malignant Pericardial Effusion? Front Oncol 2022; 12:871132. [PMID: 35600364 PMCID: PMC9120828 DOI: 10.3389/fonc.2022.871132] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2022] [Accepted: 04/11/2022] [Indexed: 12/12/2022] Open
Abstract
Pericardial effusion is a common finding in advanced-stage lung cancer. The presence of malignant cells or drainage of exudate effusion in the pericardial space may cause symptoms of dyspnea, pleuritic chest pain, and syncope. In addition to the difficulty physicians face in the detection and diagnosis of malignant pericardial effusion, treatment may be challenging considering the cancer prognosis and cardiovascular stability of the patient. Despite the availability of several treatment modalities for malignant pericardial effusion, including chemotherapy and surgery, patients with lung cancer historically present with poor prognoses. In addition to lung adenocarcinoma with malignant pericardial effusion, this case was complicated by COVID-19 and malignancy-associated obstructive pneumonia. We present a case of a 64-year-old woman with advanced non-small cell lung carcinoma (NSCLC) with malignant pericardial effusion who, despite testing positive for COVID-19 and having obstructive pneumonia, had favorable outcomes following systemic therapy with combined chemo-immunotherapy.
Collapse
|
204
|
Della Vecchia C, Girodet M, Ginguené S, Carpentier C, Leroy T, Siméone A, Vayre E, Mabire X, Ferraz D, Morin-Messabel C, Préau M. At the heart of the COVID-19 crisis: Perceived concerns of changes in long-term cancer care in French women with cancer. Eur J Cancer Care (Engl) 2022; 31:e13599. [PMID: 35523418 PMCID: PMC9349365 DOI: 10.1111/ecc.13599] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 02/24/2022] [Accepted: 03/28/2022] [Indexed: 12/15/2022]
Abstract
Objective In the COVID‐19 crisis context, the main objective of the study is to investigate factors associated with perceived concerns of change in long‐term cancer care in patients currently under treatment. Methods A French population‐based cross‐sectional study was performed using an online questionnaire in April 2020. All persons currently receiving cancer treatment and belonging to the Seintinelles Association (https://www.seintinelles.com) were included in this present analysis. Individual sociodemographic characteristics, medical status and information regarding cancer care were collected. Multivariate binomial logistic regression analysis was performed. Results We included 298 women in the analysis. Younger participants (OR = 0.96 [0.94–0.99]), the need to visit healthcare facilities to receive treatment (OR = 2.93 [1.16–8.52]), deterioration in the quality of communication with the medical team since the beginning of the COVID‐19 crisis (OR = 3.24 [1.61–7.02]) and being cared for by a university hospital or a public hospital (OR = 2.19 [1.16–4.23] versus comprehensive cancer centre) were associated with a perceived fear of change in long‐term cancer care. Conclusion To address patients' concerns regarding changes in their long‐term cancer care, medical teams should consider the patients' own perceptions of the situation and provide clear, appropriate, precise information on cancer care, especially in the centres mostly affected by the COVID‐19 crisis.
Collapse
Affiliation(s)
- Claire Della Vecchia
- Pole of Social Psychology, Inserm U1296 Unit 'Radiation: Defense, Health Environment', Lyon 2 University, Lyon, France
| | - Magali Girodet
- Human and Social Sciences Department/Medical Evaluation and Sarcomas Team, Comprehensive Cancer Care Centre Léon Bérard, Lyon, France.,Research on Healthcare Performance (RESHAPE), Université Claude Bernard Lyon 1, Lyon, France
| | - Stéphéline Ginguené
- Pole of Social Psychology, Inserm U1296 Unit 'Radiation: Defense, Health Environment', Lyon 2 University, Lyon, France
| | - Camille Carpentier
- Pole of Social Psychology, Inserm U1296 Unit 'Radiation: Defense, Health Environment', Lyon 2 University, Lyon, France
| | - Tanguy Leroy
- Pole of Social Psychology, Inserm U1296 Unit 'Radiation: Defense, Health Environment', Lyon 2 University, Lyon, France
| | - Arnaud Siméone
- Pole of Social Psychology, Inserm U1296 Unit 'Radiation: Defense, Health Environment', Lyon 2 University, Lyon, France
| | - Emilie Vayre
- Pole of Social Psychology, Inserm U1296 Unit 'Radiation: Defense, Health Environment', Lyon 2 University, Lyon, France
| | - Xavier Mabire
- Pole of Social Psychology, Inserm U1296 Unit 'Radiation: Defense, Health Environment', Lyon 2 University, Lyon, France
| | - Dulce Ferraz
- Pole of Social Psychology, Inserm U1296 Unit 'Radiation: Defense, Health Environment', Lyon 2 University, Lyon, France.,PHASE (Psychology of Health, Aging and Sport Examination), University of Lausanne Faculty of Social and Political Science, Lausanne, Switzerland
| | - Christine Morin-Messabel
- Pole of Social Psychology, Inserm U1296 Unit 'Radiation: Defense, Health Environment', Lyon 2 University, Lyon, France
| | - Marie Préau
- Pole of Social Psychology, Inserm U1296 Unit 'Radiation: Defense, Health Environment', Lyon 2 University, Lyon, France
| |
Collapse
|
205
|
Siregar KB, Azrah A, Aryanti C. The Baseline, Clinical, and Laboratory Parameters of Breast Cancer Subjects Infected with COVID-19 in Medan, Indonesia. Open Access Maced J Med Sci 2022. [DOI: 10.3889/oamjms.2022.9116] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
Abstract
BACKGROUND: Cancer patients may be susceptible to COVID-19 infection due to decreased immune status. Breast cancer is the most common cancer in Indonesia, still has high admission, which increasing the risk of exposure to COVID-19.
AIM: Thus, this study aimed to identify hospitalized breast cancer patients diagnosed with COVID-19 infection 1 year after the pandemic.
METHODS: This is a cross-sectional study that was conducted in the Adam Malik General Hospital in Medan, Sumatera Utara, Indonesia. The enrolled subjects were those who previously histopathologically confirmed with breast cancer and having laboratory-confirmed COVID-19 infection The sources of baseline, clinical, and laboratory data were retrieved from the electronic medical records. Statistical analysis was performed using the SPSS 16.0 software (SPSS Inc., Chicago, IL, USA).
RESULTS: A total of 17 female breast cancer subjects with COVID-19 infection were enrolled in this study. Mostly subjects were multiparity, highest education was junior high school, housewife, menopause, diagnosed in Stage IV, had metastasis in lung, and categorized luminal B with invasive cancer of non-special type. Most subjects showed mild clinical and radiological severity of COVID-19 infection. Low leukocyte, high neutrophil-to-lymphocyte, and high platelet-to-lymphocyte counts were significantly differed between alive and death outcome in the subjects.
CONCLUSION: The baseline and clinical characteristics of female breast cancer subjects with COVID-19 infection were similar to general characteristics in the population. The parameters of leukocyte, neutrophil-to-lymphocyte, and platelet-to-lymphocyte counts could be a valuable predictive parameters of mortality outcomes.
Collapse
|
206
|
Rubinstein SM, Bhutani D, Lynch RC, Hsu CY, Shyr Y, Advani S, Mesa RA, Mishra S, Mundt DP, Shah DP, Sica RA, Stockerl-Goldstein KE, Stratton C, Weiss M, Beeghly-Fadiel A, Accordino M, Assouline SE, Awosika J, Bakouny Z, Bashir B, Berg S, Bilen MA, Castellano CA, Cogan JC, KC D, Friese CR, Gupta S, Hausrath D, Hwang C, Johnson NA, Joshi M, Kasi A, Klein EJ, Koshkin VS, Kuderer NM, Kwon DH, Labaki C, Latif T, Lau E, Li X, Lyman GH, McKay RR, Nagaraj G, Nizam A, Nonato TK, Olszewski AJ, Polimera HV, Portuguese AJ, Puc MM, Razavi P, Rosovski R, Schmidt A, Shah SA, Shastri A, Su C, Torka P, Wise-Draper TM, Zubiri L, Warner JL, Thompson MA, for the COVID-19 and Cancer Consortium. Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19. Blood Cancer Discov 2022; 3:181-193. [PMID: 35262738 PMCID: PMC9355598 DOI: 10.1158/2643-3230.bcd-22-0013] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/21/2022] [Revised: 02/07/2022] [Accepted: 03/05/2022] [Indexed: 12/15/2022] Open
Abstract
Patients with B-lymphoid malignancies have been consistently identified as a population at high risk of severe COVID-19. Whether this is exclusively due to cancer-related deficits in humoral and cellular immunity, or whether risk of severe COVID-19 is increased by anticancer therapy, is uncertain. Using data derived from the COVID-19 and Cancer Consortium (CCC19), we show that patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non-B-lymphoid malignancies. Among patients with B-lymphoid malignancies, those who received anticancer therapy within 12 months of COVID-19 diagnosis experienced increased COVID-19 severity compared with patients with non-recently treated B-lymphoid malignancies, after adjustment for cancer status and several other prognostic factors. Our findings suggest that patients recently treated for a B-lymphoid malignancy are at uniquely high risk for severe COVID-19. SIGNIFICANCE Our study suggests that recent therapy for a B-lymphoid malignancy is an independent risk factor for COVID-19 severity. These findings provide rationale to develop mitigation strategies targeted at the uniquely high-risk population of patients with recently treated B-lymphoid malignancies. This article is highlighted in the In This Issue feature, p. 171.
Collapse
Affiliation(s)
- Samuel M. Rubinstein
- Division of Hematology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina
| | - Divaya Bhutani
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York
| | - Ryan C. Lynch
- Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington
| | - Chih-Yuan Hsu
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Yu Shyr
- Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Shailesh Advani
- Cancer Prevention and Control, Department of Oncology, Georgetown University School of Medicine, Georgetown University, Washington D.C
| | - Ruben A. Mesa
- Mays Cancer Center, UT Health San Antonio MD Anderson, San Antonio, Texas
| | - Sanjay Mishra
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Daniel P. Mundt
- Aurora Cancer Care, Advocate Aurora Health, Milwaukee, Wisconsin
| | - Dimpy P. Shah
- Mays Cancer Center, UT Health San Antonio MD Anderson, San Antonio, Texas
| | - R. Alejandro Sica
- Division of Hematology and Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York
| | | | - Catherine Stratton
- Division of Hematology and Oncology, Yale University, New Haven, Connecticut
| | | | - Alicia Beeghly-Fadiel
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Melissa Accordino
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York
| | - Sarit E. Assouline
- Division of Hematology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada
| | - Joy Awosika
- University of Cincinnati Cancer Center, Cincinnati, Ohio
| | - Ziad Bakouny
- Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Babar Bashir
- Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania
| | - Stephanie Berg
- Division of Hematology and Oncology, Loyola University Medical Center, Hines, Illinois
| | | | | | - Jacob C. Cogan
- Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York
| | - Devendra KC
- Hartford HealthCare Cancer Institute, Hartford, Connecticut
| | | | - Shilpa Gupta
- Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
| | - Daniel Hausrath
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Clara Hwang
- Henry Ford Cancer Institute, Henry Ford Hospital, Detroit, Michigan
| | - Nathalie A. Johnson
- Division of Hematology, McGill University, Jewish General Hospital, Montreal, Quebec, Canada
| | - Monika Joshi
- Penn State Health/Penn State Cancer Institute/St. Joseph Cancer Center, Philadelphia, Pennsylvania
| | - Anup Kasi
- The University of Kansas Cancer Center, Kansas City, Kansas
| | - Elizabeth J. Klein
- Brown University and Lifespan Cancer Institute, Providence, Rhode Island
| | - Vadim S. Koshkin
- Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California
| | | | - Daniel H. Kwon
- Helen Diller Family Comprehensive Cancer Center, University of California at San Francisco, San Francisco, California
| | - Chris Labaki
- Dana-Farber Cancer Institute, Boston, Massachusetts
| | - Tahir Latif
- University of Cincinnati Cancer Center, Cincinnati, Ohio
| | - Eric Lau
- Division of Medical Oncology and Hematology, Loma Linda University, Loma Linda, California
| | - Xuanyi Li
- Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee
| | - Gary H. Lyman
- Fred Hutchinson Cancer Research Center, Seattle, Washington
| | - Rana R. McKay
- Moores Comprehensive Cancer Center, University of California, San Diego, San Diego, California
| | - Gayathri Nagaraj
- Division of Medical Oncology and Hematology, Loma Linda University, Loma Linda, California
| | - Amanda Nizam
- Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio
| | - Taylor K. Nonato
- Moores Comprehensive Cancer Center, University of California, San Diego, San Diego, California
| | - Adam J. Olszewski
- Brown University and Lifespan Cancer Institute, Providence, Rhode Island
| | - Hyma V. Polimera
- Penn State Health/Penn State Cancer Institute/St. Joseph Cancer Center, Philadelphia, Pennsylvania
| | - Andrew J. Portuguese
- Department of Medicine, Division of Medical Oncology, University of Washington, Seattle, Washington
| | | | - Pedram Razavi
- Moores Comprehensive Cancer Center, University of California, San Diego, San Diego, California
| | - Rachel Rosovski
- Division of Hematology, Massachusetts General Hospital, Boston, Massachusetts
| | | | - Sumit A. Shah
- Stanford Cancer Institute at Stanford University, Stanford, California
| | - Aditi Shastri
- Division of Hematology and Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York
| | - Christopher Su
- University of Michigan Rogel Cancer Center, Ann Arbor, Michigan
| | - Pallawi Torka
- Roswell Park Comprehensive Cancer Center, New York, New York
| | | | | | - Jeremy L. Warner
- Department of Health Policy, Vanderbilt University Medical Center, Nashville, Tennessee
- Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, Tennessee
| | | | | |
Collapse
|
207
|
Khoury E, Nevitt S, Madsen WR, Turtle L, Davies G, Palmieri C. Differences in Outcomes and Factors Associated With Mortality Among Patients With SARS-CoV-2 Infection and Cancer Compared With Those Without Cancer: A Systematic Review and Meta-analysis. JAMA Netw Open 2022; 5:e2210880. [PMID: 35532936 PMCID: PMC9086843 DOI: 10.1001/jamanetworkopen.2022.10880] [Citation(s) in RCA: 57] [Impact Index Per Article: 19.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/11/2022] [Accepted: 03/21/2022] [Indexed: 12/14/2022] Open
Abstract
Importance SARS-CoV-2 infection has been associated with more severe disease and death in patients with cancer. However, the implications of certain tumor types, treatments, and the age and sex of patients with cancer for the outcomes of COVID-19 remain unclear. Objective To assess the differences in clinical outcomes between patients with cancer and SARS-CoV-2 infection and patients without cancer but with SARS-CoV-2 infection, and to identify patients with cancer at particularly high risk for a poor outcome. Data Sources PubMed, Web of Science, and Scopus databases were searched for articles published in English until June 14, 2021. References in these articles were reviewed for additional studies. Study Selection All case-control or cohort studies were included that involved 10 or more patients with malignant disease and SARS-CoV-2 infection with or without a control group (defined as patients without cancer but with SARS-CoV-2 infection). Studies were excluded if they involved fewer than 10 patients, were conference papers or abstracts, were preprint reports, had no full text, or had data that could not be obtained from the corresponding author. Data Extraction and Synthesis Two investigators independently performed data extraction using the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline. Meta-analysis was performed using a random-effects model. Main Outcomes and Measures The difference in mortality between patients with cancer and SARS-CoV-2 infection and control patients as well as the difference in outcomes for various tumor types and cancer treatments. Pooled case fatality rates, a random-effects model, and random-effects meta-regressions were used. Results A total of 81 studies were included, involving 61 532 patients with cancer. Among 58 849 patients with available data, 30 557 male individuals (52%) were included and median age ranged from 35 to 74 years. The relative risk (RR) of mortality from COVID-19 among patients with vs without cancer when age and sex were matched was 1.69 (95% CI, 1.46-1.95; P < .001; I2 = 51.0%). The RR of mortality in patients with cancer vs control patients was associated with decreasing age (exp [b], 0.96; 95% CI, 0.92-0.99; P = .03). Compared with other cancers, lung cancer (RR, 1.68; 95% CI, 1.45-1.94; P < .001; I2 = 32.9%), and hematologic cancer (RR, 1.42; 95% CI, 1.31-1.54; P < .001; I2 = 6.8%) were associated with a higher risk of death. Although a higher point estimate was found for genitourinary cancer (RR, 1.11; 95% CI, 1.00-1.24; P = .06; I2 = 21.5%), the finding was not statistically significant. Breast cancer (RR, 0.51; 95% CI, 0.36-0.71; P < .001; I2 = 86.2%) and gynecological cancer (RR, 0.76; 95% CI, 0.62-0.93; P = .009; I2 = 0%) were associated with a lower risk of death. Chemotherapy was associated with the highest overall pooled case fatality rate of 30% (95% CI, 25%-36%; I2 = 86.97%; range, 10%-100%), and endocrine therapy was associated with the lowest at 11% (95% CI, 6%-16%; I2 = 70.68%; range, 0%-27%). Conclusions and Relevance Results of this study suggest that patients with cancer and SARS-CoV-2 infection had a higher risk of death than patients without cancer. Younger age, lung cancer, and hematologic cancer were also risk factors associated with poor outcomes from COVID-19.
Collapse
Affiliation(s)
- Emma Khoury
- Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom
- University of Liverpool, School of Medicine, Liverpool, United Kingdom
| | - Sarah Nevitt
- Department of Health Data Science, Institute of Population Health, University of Liverpool, United Kingdom
| | - William Rohde Madsen
- Department of Political Science and School of Public Policy, University College London, London, United Kingdom
- Department of Political Science, University of Copenhagen, Copenhagen, Denmark
| | - Lance Turtle
- Tropical and Infectious Disease Unit, Liverpool University Hospitals National Health Service (NHS) Foundation Trust, Member of Liverpool Health Partners, Liverpool, United Kingdom
| | - Gerry Davies
- Department of Clinical Infection Microbiology and Immunology, Department of Clinical Infection, University of Liverpool, Liverpool, United Kingdom
- University of Liverpool Institute of Infection and Global Health, Veterinary and Ecological Sciences, Liverpool, United Kingdom
| | - Carlo Palmieri
- Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Institute of Translational Medicine, Liverpool, United Kingdom
- The Clatterbridge Cancer Centre NHS Foundation Trust, Liverpool, United Kingdom
| |
Collapse
|
208
|
Hassan M, Le UT, Grapatsas K, Passlick B, Schmid S. Onkologische Thoraxchirurgie während der COVID-19-Pandemie: eine Fallkontrollstudie zum Risiko für postoperative Komplikationen. TUMORDIAGNOSTIK & THERAPIE 2022; 43:268-274. [DOI: 10.1055/a-1795-8011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/05/2025]
Abstract
Zusammenfassung
Hintergrund Die COVID-19-Pandemie hatte, neben der
offensichtlichen Bedeutung als eigenständige Erkrankung, einen schwerwiegenden Einfluss auf
alle Aspekte der medizinischen Versorgung. In der onkologischen Chirurgie mussten Operationen
verschoben werden oder es kam zu verzögerten Diagnosen onkologischer Erkrankungen, was neben
der Sorge um unzureichende Ressourcen auch in der Unsicherheit bezüglich der perioperativen
Risiken begründet lag. In dieser Studie untersuchen wir die Sicherheit der Durchführung
onkologischer thoraxchirurgischer Eingriffe während der COVID-19-Pandemie.
Patienten und Methoden Es wurden retrospektiv die Ergebnisse der
thoraxchirurgischen Operationen bei onkologischen Patienten am Universitätsklinikum Freiburg
während der 1., 2. und 3. Welle der COVID-19-Pandemie (vom 01.01. bis 30.04.2020 sowie vom
01.01. bis 30.04.2021) untersucht. Als Kontrollgruppe wurden die im gleichen Zeitraum vor der
Pandemie (2018 und 2019) durchgeführten Operationen gewählt. Der primäre Endpunkt war das
Auftreten postoperativer Komplikationen.
Ergebnisse 236 Operationen in der Pandemiekohorte und 227
Operationen in der Kontrollkohorte wurden in die Studie eingeschlossen. Es gab keinen
Unterschied in der Inzidenzrate von postoperativen Minor-Komplikationen (16,1% vs. 18,5%,
p = 0,5395) oder Major-Komplikationen (12,2% vs. 10,13%, p = 0,5563) zwischen der
Pandemiekohorte und der Kontrollkohorte. Es zeigte sich kein erhöhtes Risiko für postoperative
pulmonale Komplikationen in der Pandemiekohorte (Odds Ratio = 1,193, 95%-KI= 0,6515–2,203,
p = 0,8232). Eine COVID-19-Infektion nach der Operation trat bei 5 Patienten der
Pandemiekohorte auf (2,29%). Die postoperative Motilität innerhalb von 30 Tagen waren
vergleichbar zwischen der Pandemiekohorte und der Kontrollkohorte (2 (0,85%) vs. 1 (0,44%),
p > 0,9999). Es gab keine COVID-19-infektionsbedingte Mortalität.
Schlussfolgerung Die Durchführung von onkologischen
thoraxchirurgischen Operationen während der COVID-19-Pandemie ist, unter Einhaltung der
entsprechenden Sicherheitsmaßnahmen, sicher und weder mit einer erhöhten Komplikationsrate
noch einer erhöhten Mortalität verbunden.
Collapse
Affiliation(s)
- Mohamed Hassan
- Klinik für Thoraxchirurgie, Universitätsklinikum Freiburg, Freiburg, Deutschland
| | - Uyen-Thao Le
- Klinik für Thoraxchirurgie, Universitätsklinikum Freiburg, Freiburg, Deutschland
| | | | - Bernward Passlick
- Klinik für Thoraxchirurgie, Universitätsklinikum Freiburg, Freiburg, Deutschland
| | - Severin Schmid
- Klinik für Thoraxchirurgie, Universitätsklinikum Freiburg, Freiburg, Deutschland
| |
Collapse
|
209
|
Abstract
We analyze risk factors correlated with the initial transmission growth rate of the recent COVID-19 pandemic in different countries. The number of cases follows in its early stages an almost exponential expansion; we chose as a starting point in each country the first day di with 30 cases and we fitted for 12 days, capturing thus the early exponential growth. We looked then for linear correlations of the exponents α with other variables, for a sample of 126 countries. We find a positive correlation, i.e. faster spread of COVID-19, with high confidence level with the following variables, with respective p-value: low Temperature (4⋅10-7), high ratio of old vs. working-age people (3⋅10-6), life expectancy (8⋅10-6), number of international tourists (1⋅10-5), earlier epidemic starting date di (2⋅10-5), high level of physical contact in greeting habits (6⋅10-5), lung cancer prevalence (6⋅10-5), obesity in males (1⋅10-4), share of population in urban areas (2⋅10-4), cancer prevalence (3⋅10-4), alcohol consumption (0.0019), daily smoking prevalence (0.0036), and UV index (0.004, 73 countries). We also find a correlation with low Vitamin D serum levels (0.002-0.006), but on a smaller sample, ∼50 countries, to be confirmed on a larger sample. There is highly significant correlation also with blood types: positive correlation with types RH- (3⋅10-5) and A+ (3⋅10-3), negative correlation with B+ (2⋅10-4). We also find positive correlation with moderate confidence level (p-value of 0.02∼0.03) with: CO2/SO emissions, type-1 diabetes in children, low vaccination coverage for Tuberculosis (BCG). Several of the above variables are correlated with each other, and so they are likely to have common interpretations. We thus performed a Principal Component Analysis, to find the significant independent linear combinations of such variables. The variables with loadings of at least 0.3 on the significant PCA are: greeting habits, urbanization, epidemic starting date, number of international tourists, temperature, lung cancer, smoking, and obesity in males. We also analyzed the possible existence of a bias: countries with low GDP-per capita might have less intense testing, and we discuss correlation with the above variables.
Collapse
Affiliation(s)
- Alessio Notari
- Departament de Física Quàntica i Astrofisíca & Institut de Ciències del Cosmos (ICCUB), Universitat de Barcelona, Barcelona, Spain
| | | |
Collapse
|
210
|
Naimi A, Yashmi I, Jebeleh R, Imani Mofrad M, Azimian Abhar S, Jannesar Y, Heidary M, Pakzad R. Comorbidities and mortality rate in COVID-19 patients with hematological malignancies: A systematic review and meta-analysis. J Clin Lab Anal 2022; 36:e24387. [PMID: 35385130 PMCID: PMC9102765 DOI: 10.1002/jcla.24387] [Citation(s) in RCA: 23] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/17/2022] [Revised: 03/15/2022] [Accepted: 03/18/2022] [Indexed: 12/11/2022] Open
Abstract
INTRODUCTION The global pandemic of coronavirus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). It seems that there is an association between blood cancer and an increased risk of severe COVID-19. This study aimed to review the literature reporting the COVID-19 outcomes in patients with hematological malignancies. MATERIAL AND METHODS In this systematic review and meta-analysis, Pubmed, Embase, and Web of Science databases were searched using the following keywords: COVID-19, SARS-CoV-2, blood cancer, myeloma, lymphoma, and leukemia. All the published articles in English from January 1, 2019, until March 10, 2021 were collected and evaluated. RESULTS In total, 53 studies with 2395 patients were included based on inclusion criteria. Most of these studies took place in Spain (14.81%), followed by the USA (11.11%), China (9.26%), and the UK (9.26%). More than half of COVID-19 patients with hematological malignancy were male (56.73%). Oxygen therapy played an important role in COVID-19 treatment. Moreover, anticoagulant therapies such as enoxaparin and heparin were two great assists for these patients. Fever (74.24%), cough (67.64%), and fatigue (53.19%) were the most reported clinical manifestations. In addition, hypertension and dyslipidemia were the most common comorbidities. The mortality rate due to COVID-19 in patients with hematological malignancies was 21.34%. CONCLUSION This study demonstrated that hematologic cancer patients were more susceptible to a severe COVID-19 than patients without blood cancer. Thus, the management of COVID-19 in these patients requires much more attention, and their screening should perform regularly.
Collapse
Affiliation(s)
- Adel Naimi
- Cellular and Molecular Research CenterSabzevar University of Medical SciencesSabzevarIran
| | - Ilya Yashmi
- Student Research CommitteeSabzevar University of Medical SciencesSabzevarIran
| | - Reza Jebeleh
- Student Research CommitteeSabzevar University of Medical SciencesSabzevarIran
| | | | | | - Yasaman Jannesar
- Student Research CommitteeSabzevar University of Medical SciencesSabzevarIran
| | - Mohsen Heidary
- Cellular and Molecular Research CenterSabzevar University of Medical SciencesSabzevarIran
- Department of Laboratory SciencesSchool of Paramedical SciencesSabzevar University of Medical SciencesSabzevarIran
| | - Reza Pakzad
- Department of EpidemiologyFaculty of HealthIlam University of Medical SciencesIlamIran
| |
Collapse
|
211
|
Notari A, Torrieri G. COVID-19 transmission risk factors. Pathog Glob Health 2022; 116:146-177. [PMID: 34962231 PMCID: PMC8787846 DOI: 10.1080/20477724.2021.1993676] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Abstract
We analyze risk factors correlated with the initial transmission growth rate of the recent COVID-19 pandemic in different countries. The number of cases follows in its early stages an almost exponential expansion; we chose as a starting point in each country the first day d i with 30 cases and we fitted for 12 days, capturing thus the early exponential growth. We looked then for linear correlations of the exponents α with other variables, for a sample of 126 countries. We find a positive correlation, i.e. faster spread of COVID-19, with high confidence level with the following variables, with respective p -value: low Temperature (4 ⋅ 10 - 7 ), high ratio of old vs. working-age people (3 ⋅ 10 - 6 ), life expectancy (8 ⋅ 10 - 6 ), number of international tourists (1 ⋅ 10 - 5 ), earlier epidemic starting date d i (2 ⋅ 10 - 5 ), high level of physical contact in greeting habits (6 ⋅ 10 - 5 ), lung cancer prevalence (6 ⋅ 10 - 5 ), obesity in males (1 ⋅ 10 - 4 ), share of population in urban areas (2 ⋅ 10 - 4 ), cancer prevalence (3 ⋅ 10 - 4 ), alcohol consumption (0.0019 ), daily smoking prevalence (0.0036 ), and UV index (0.004 , 73 countries). We also find a correlation with low Vitamin D serum levels (0.002 - 0.006 ), but on a smaller sample, ∼ 50 countries, to be confirmed on a larger sample. There is highly significant correlation also with blood types: positive correlation with types RH- (3 ⋅ 10 - 5 ) and A+ (3 ⋅ 10 - 3 ), negative correlation with B+ (2 ⋅ 10 - 4 ). We also find positive correlation with moderate confidence level (p -value of 0.02 ∼ 0.03 ) with: CO2/SO emissions, type-1 diabetes in children, low vaccination coverage for Tuberculosis (BCG). Several of the above variables are correlated with each other, and so they are likely to have common interpretations. We thus performed a Principal Component Analysis, to find the significant independent linear combinations of such variables. The variables with loadings of at least 0.3 on the significant PCA are: greeting habits, urbanization, epidemic starting date, number of international tourists, temperature, lung cancer, smoking, and obesity in males. We also analyzed the possible existence of a bias: countries with low GDP-per capita might have less intense testing, and we discuss correlation with the above variables.
Collapse
Affiliation(s)
- Alessio Notari
- Departament de Física Quàntica i Astrofisíca & Institut de Ciències del Cosmos (ICCUB), Universitat de Barcelona, Barcelona, Spain
| | | |
Collapse
|
212
|
Allali S, Beddok A, Kirova Y. Is cancer a prognostic factor for severe COVID-19, especially for breast cancer patients? Cancer Radiother 2022; 26:491-493. [PMID: 34274225 PMCID: PMC8245377 DOI: 10.1016/j.canrad.2021.06.015] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2021] [Revised: 06/08/2021] [Accepted: 06/16/2021] [Indexed: 12/15/2022]
Abstract
The coronavirus disease 2019 (COVID-19) pandemic has caused a global upheaval in our health care system. Our hospital facilities have been subjected to a major influx of patients and the prevention of cross-contamination has been a key issue in the spread of the virus. New recommendations for good hygiene practice and new recommendations for disease management have emerged to limit the spread of the virus and reorganize the provision of care in key services. Many studies have attempted to identify factors that contribute to poor prognosis for COVID-19 infection. Among them, cancer patients, were considered more at risk of developing severe forms of COVID-19. In this article, we provide an overview of the current state of the pandemic as well as new recommendations for disease management that have emerged in oncology and radiation therapy in particular. In this article, we will try to provide some answers through a review of the literature to the question: is cancer a prognostic factor for severe COVID-19?
Collapse
Affiliation(s)
- S. Allali
- Department of Radiation Oncology, Institut Curie, 26, rue d’Ulm, 75005 Paris, France
| | - A. Beddok
- Department of Radiation Oncology, Institut Curie, 26, rue d’Ulm, 75005 Paris, France
| | - Y. Kirova
- Department of Radiation Oncology, Institut Curie, 26, rue d’Ulm, 75005 Paris, France,Université Versailles Saint-Quentin, 78000 Versailles, France,Corresponding author
| |
Collapse
|
213
|
Impact of the COVID-19 Pandemic on Oncology Patients’ Mental Health and Treatment Plans. Healthcare (Basel) 2022; 10:healthcare10050825. [PMID: 35627962 PMCID: PMC9141433 DOI: 10.3390/healthcare10050825] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Revised: 04/21/2022] [Accepted: 04/27/2022] [Indexed: 12/10/2022] Open
Abstract
The COVID-19 pandemic has disrupted cancer care to a certain degree. There is objective evidence that COVID-19 outbreaks are causing substantial emotional distress among cancer patients regardless of their disease severity. This study aims to measure the levels of psychological distress, depression, and pandemic anxiety among cancer patients in Saudi Arabia during the outbreak of COVID-19 and their impact on patients’ cancer treatment plans. Methods: This was a cross-sectional study conducted among oncology patients in Saudi Arabia in November of 2020. The levels of stress, depression, and anxiety symptoms during the COVID-19 outbreak were measured using the Questionnaire for Depression and Anxiety (PHQ-4), and patients were classified as depressed/distressed if the total score was 6 and above and classified as not depressed/distressed if they scored less than 6. Results: Among the sampled population, anxiety symptoms and depression were detected in 61.5% and 70.2%, respectively. Statistical analyses revealed that feeling more isolated was significant for anxiety symptoms (p = 0.005), while patients who used institutions as a source of COVID-19 information had significant depression (p = 0.010) compared to patients who accessed information from other sources. In the binary regression model, feeling more isolated than before was 3.208 times more likely to be associated with anxiety symptoms (OR = 3.208; 95% CI = 1.391–7.396; p = 0.006), while those patients who had a support institution as a source of COVID-19 information were 4.2 times more likely to be associated with depression (OR = 4.200; 95% CI = 1.328–13.280; p = 0.015). Conclusion: The COVID-19 pandemic has added to the burden on cancer patients. The increased risk of anxiety symptoms and depression was clearly demonstrated in this study. Feeling isolated had a greater impact on anxiety symptoms, while obtaining COVID-19 information from a patient support institution negatively affected depression.
Collapse
|
214
|
Outcomes of Cancer Patients with COVID-19 in a Hospital System in the Chicago Metropolitan Area. Cancers (Basel) 2022; 14:cancers14092209. [PMID: 35565336 PMCID: PMC9105648 DOI: 10.3390/cancers14092209] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Revised: 04/09/2022] [Accepted: 04/19/2022] [Indexed: 01/27/2023] Open
Abstract
Patients with a history of malignancy have been shown to be at an increased risk of COVID-19-related morbidity and mortality. Poorer clinical outcomes in that patient population are likely due to the underlying systemic illness, comorbidities, and the cytotoxic and immunosuppressive anti-tumor treatments they are subjected to. We identified 416 cancer patients with SARS-CoV-2 infection being managed for their malignancy at Northwestern Medicine in Chicago, Illinois, between March and July of 2020. Seventy-five (18.0%) patients died due to COVID-related complications. Older age (>60), male gender, and current treatment with immunotherapy were associated with shorter overall survival. Laboratory findings showed that higher platelet counts, ALC, and hemoglobin were protective against critical illness and death from COVID-19. Conversely, elevated inflammatory markers such as ferritin, d-dimer, procalcitonin, CRP, and LDH led to worse clinical outcomes. Our findings suggest that a thorough clinical and laboratory assessment of infected patients with cancer might help identify a more vulnerable population and implement more aggressive proactive strategies.
Collapse
|
215
|
Joerger M, Metaxas Y, Zaman K, Michielin O, Mach N, Bettini A, Schmitt AM, Cantoni N, Caspar CB, Stettler S, Malval R, Pless M, Britschgi C, Renner C, Koeberle D, Schulz JD, Kopp C, Hayoz S, Stathis A, von Moos R. Outcome and Prognostic Factors of COVID-19 Infection in Swiss Cancer Patients: Final Results of SAKK 80/20 (CaSA). Cancers (Basel) 2022; 14:2191. [PMID: 35565320 PMCID: PMC9104745 DOI: 10.3390/cancers14092191] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/27/2022] [Revised: 04/24/2022] [Accepted: 04/25/2022] [Indexed: 02/04/2023] Open
Abstract
Purpose: These are the final results of a national registry on cancer patients with COVID-19 in Switzerland. Methods: We collected data on symptomatic COVID-19-infected cancer patients from 23 Swiss sites over a one-year period starting on 1 March 2020. The main objective was to assess the outcome (i.e., mortality, rate of hospitalization, ICU admission) of COVID-19 infection in cancer patients; the main secondary objective was to define prognostic factors. Results: From 455 patients included, 205 patients (45%) had non-curative disease, 241 patients (53%) were hospitalized for COVID-19, 213 (47%) required oxygen, 43 (9%) invasive ventilation and 62 (14%) were admitted to the ICU. Death from COVID-19 infection occurred in 98 patients, resulting in a mortality rate of 21.5%. Age ≥65 years versus <65 years (OR 3.14, p = 0.003), non-curative versus curative disease (OR 2.42, p = 0.012), ICU admission (OR 4.45, p < 0.001) and oxygen requirement (OR 20.28, p < 0.001) were independently associated with increased mortality. Conclusions: We confirmed high COVID-19 severity and mortality in real-world cancer patients during the first and second wave of the pandemic in a country with a decentralized, high-quality, universal-access health care system. COVID-19-associated mortality was particularly high for those of older age in a non-curative disease setting, requiring oxygen or ICU care.
Collapse
Affiliation(s)
- Markus Joerger
- Department of Oncology, Cantonal Hospital, 9007 St. Gallen, Switzerland
| | - Yannis Metaxas
- Department of Medical Oncology, Cantonal Hospital, 8596 Muensterlingen, Switzerland;
| | - Khalil Zaman
- Breast Center, Department of Medical Oncology, University Hospital, 1011 Lausanne, Switzerland;
| | - Olivier Michielin
- Department of Medical Oncology, University Hospital, 1011 Lausanne, Switzerland;
| | - Nicolas Mach
- Department of Medical Oncology, University Hospital, 1205 Geneva, Switzerland;
| | - Adrienne Bettini
- Department of Medical Oncology, HFR Fribourg-Hôpital Cantonal, 1752 Fribourg, Switzerland;
| | - Andreas M. Schmitt
- Department of Medical Oncology, University Hospital, 4031 Basel, Switzerland;
| | - Nathan Cantoni
- Oncology, Hematology and Transfusion Medicine, Cantonal Hospital, 5001 Aarau, Switzerland;
| | - Clemens B. Caspar
- Division of Hematology and Oncology, Cantonal Hospital, 5404 Baden, Switzerland;
| | - Sonja Stettler
- Division of Medical Oncology, Lucerne Cantonal Hospital, 6000 Lucerne, Switzerland;
| | | | - Miklos Pless
- Division of Medical Oncology and Hematology, Cantonal Hospital, 8400 Winterthur, Switzerland;
| | - Christian Britschgi
- Department of Medical Oncology and Hematology, University Hospital, 8091 Zurich, Switzerland;
| | - Christoph Renner
- Department of Medical Oncology, Oncological Center Zurich, 8038 Zurich, Switzerland;
| | - Dieter Koeberle
- Department of Oncology, Claraspital, 4058 Basel, Switzerland;
| | - Jessica D. Schulz
- SAKK Coordinating Center, 3008 Bern, Switzerland; (J.D.S.); (C.K.); (S.H.)
| | - Christoph Kopp
- SAKK Coordinating Center, 3008 Bern, Switzerland; (J.D.S.); (C.K.); (S.H.)
| | - Stefanie Hayoz
- SAKK Coordinating Center, 3008 Bern, Switzerland; (J.D.S.); (C.K.); (S.H.)
| | - Anastasios Stathis
- Oncology Institute of Southern Switzerland, 6500 Bellinzona, Switzerland;
| | - Roger von Moos
- Department of Medical Oncology/Hematology, Cantonal Hospital Graubuenden, 7000 Chur, Switzerland;
| |
Collapse
|
216
|
Exploring the Utility of NK Cells in COVID-19. Biomedicines 2022; 10:biomedicines10051002. [PMID: 35625739 PMCID: PMC9138257 DOI: 10.3390/biomedicines10051002] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/28/2022] [Revised: 04/22/2022] [Accepted: 04/25/2022] [Indexed: 02/07/2023] Open
Abstract
Coronavirus disease 2019 (COVID-19) can manifest as acute respiratory distress syndrome and is associated with substantial morbidity and mortality. Extensive data now indicate that immune responses to SARS-CoV-2 infection determine the COVID-19 disease course. A wide range of immunomodulatory agents have been tested for the treatment of COVID-19. Natural killer (NK) cells play an important role in antiviral innate immunity, and anti-SARS-CoV-2 activity and antifibrotic activity are particularly critical for COVID-19 control. Notably, SARS-CoV-2 clearance rate, antibody response, and disease progression in COVID-19 correlate with NK cell status, and NK cell dysfunction is linked with increased SARS-CoV-2 susceptibility. Thus, NK cells function as the key element in the switch from effective to harmful immune responses in COVID-19. However, dysregulation of NK cells has been observed in COVID-19 patients, exhibiting depletion and dysfunction, which correlate with COVID-19 severity; this dysregulation perhaps contributes to disease progression. Given these findings, NK-cell-based therapies with anti-SARS-CoV-2 activity, antifibrotic activity, and strong safety profiles for cancers may encourage the rapid application of functional NK cells as a potential therapeutic strategy to eliminate SARS-CoV-2-infected cells at an early stage, facilitate immune–immune cell interactions, and favor inflammatory processes that prevent and/or reverse over-inflammation and inhibit fibrosis progression, thereby helping in the fight against COVID-19. However, our understanding of the role of NK cells in COVID-19 remains incomplete, and further research on the involvement of NK cells in the pathogenesis of COVID-19 is needed. The rationale of NK-cell-based therapies for COVID-19 has to be based on the timing of therapeutic interventions and disease severity, which may be determined by the balance between beneficial antiviral and potential detrimental pathologic actions. NK cells would be more effective early in SARS-CoV-2 infection and prevent the progression of COVID-19. Immunomodulation by NK cells towards regulatory functions could be useful as an adjunct therapy to prevent the progression of COVID-19.
Collapse
|
217
|
Plais H, Labruyère M, Creutin T, Nay P, Plantefeve G, Tapponnier R, Jonas M, Ngapmen NT, Le Guennec L, De Roquetaillade C, Argaud L, Jamme M, Goulenok C, Merouani K, Leclerc M, Sauneuf B, Shidasp S, Stoclin A, Bardet A, Mir O, Ibrahimi N, Llitjos JF. Outcomes of Patients With Active Cancer and COVID-19 in the Intensive-Care Unit: A Multicenter Ambispective Study. Front Oncol 2022; 12:858276. [PMID: 35359407 PMCID: PMC8960921 DOI: 10.3389/fonc.2022.858276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Accepted: 02/16/2022] [Indexed: 01/15/2023] Open
Abstract
Background Several studies report an increased susceptibility to SARS-CoV-2 infection in cancer patients. However, data in the intensive care unit (ICU) are scarce. Research Question We aimed to investigate the association between active cancer and mortality among patients requiring organ support in the ICU. Study Design and Methods In this ambispective study encompassing 17 hospitals in France, we included all adult active cancer patients with SARS-CoV-2 infection requiring organ support and admitted in ICU. For each cancer patient, we included 3 non cancer patients as controls. Patients were matched at the same ratio using the inverse probability weighting approach based on a propensity score assessing the probability of cancer at admission. Mortality at day 60 after ICU admission was compared between cancer patients and non-cancer patients using primary logistic regression analysis and secondary multivariable analyses. Results Between March 12, 2020 and March 8, 2021, 2608 patients were admitted with SARS-CoV-2 infection in our study, accounting for 2.8% of the total population of patients with SARS-CoV-2 admitted in all French ICUs within the same period. Among them, 105 (n=4%) presented with cancer (51 patients had hematological malignancy and 54 patients had solid tumors). 409 of 420 patients were included in the propensity score matching process, of whom 307 patients in the non-cancer group and 102 patients in the cancer group. 145 patients (35%) died in the ICU at day 60, 59 (56%) with cancer and 86 (27%) without cancer. In the primary logistic regression analysis, the odds ratio for death associated to cancer was 2.3 (95%CI 1.24 - 4.28, p=0.0082) higher for cancer patients than for a non-cancer patient at ICU admission. Exploratory multivariable analyses showed that solid tumor (OR: 2.344 (0.87-6.31), p=0.062) and hematological malignancies (OR: 4.144 (1.24-13.83), p=0.062) were independently associated with mortality. Interpretation Patients with cancer and requiring ICU admission for SARS-CoV-2 infection had an increased mortality, hematological malignancy harboring the higher risk in comparison to solid tumors.
Collapse
Affiliation(s)
- Henri Plais
- Intensive Care Unit, Gustave Roussy, Université Paris-Saclay, Villejuif, France
| | - Marie Labruyère
- Department of Intensive Care, Dijon Bourgogne University Hospital, Dijon, France
| | - Thibault Creutin
- Service de Médecine Intensive and Réanimation, APHP-CUP, Hôpital Cochin, Paris, France
| | - Paula Nay
- Medical Intensive Care Unit, Ambroise Paré Hospital, AP-HP, Boulogne-Billancourt, France
| | - Gaëtan Plantefeve
- Service de Réanimation Polyvalente, Centre Hospitalier Victor Dupouy, Argenteuil, France
| | - Romain Tapponnier
- Medical Intensive Care Unit, Hôpital Jean Minjoz Hospital, Besançon, France
| | - Maud Jonas
- Centre Hospitalier Général de Saint-Nazaire, Service de Médecine Intensive Réanimation, Saint-Nazaire, France
| | | | - Loïc Le Guennec
- Médecine Intensive Réanimation Neurologique, Département de Neurologie, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Charles De Roquetaillade
- Department of Anesthesiology and Critical Care, Hôpital Lariboisière, FHU PROMICE, DMU Parabol, APHP, Paris, France
| | - Laurent Argaud
- Medical ICU, Edouard Herriot University Hospital, Lyon, France
| | - Matthieu Jamme
- Intensive Care Unit, Poissy-Saint-Germain-en-Laye Hospital, Poissy, France
| | - Cyril Goulenok
- Medical-Surgical Intensive Care Unit, Ramsay Générale de Santé, Hôpital Privé Jacques Cartier, Massy, France
| | - Karim Merouani
- Medical and Surgical Intensive Care Unit, Alençon Hospital, Alençon, France
| | - Maxime Leclerc
- Intensive Care Unit, Centre Hospitalier Mémorial France Etats-Unis, Saint-Lô, France
| | - Bertrand Sauneuf
- Réanimation - Médecine Intensive, Centre Hospitalier Public du Cotentin, Cherbourg-en-Cotentin, France
| | - Sami Shidasp
- Intensive Care Unit, Etampes Hospital, Etampes, France
| | - Annabelle Stoclin
- Intensive Care Unit, Centre Hospitalier de Château-Thierry, Château-Thierry, France
| | - Aurélie Bardet
- Bureau of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France and U1018 INSERM Oncostat, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France
| | - Olivier Mir
- Gustave-Roussy, Département d'oncologie Médicale, Villejuif, France
| | - Nusaibah Ibrahimi
- Bureau of Biostatistics and Epidemiology, Gustave Roussy, University Paris-Saclay, Villejuif, France and U1018 INSERM Oncostat, University Paris-Saclay, Labeled Ligue Contre le Cancer, Villejuif, France
| | | |
Collapse
|
218
|
Affiliation(s)
- Joseph M Unger
- Fred Hutchinson Cancer Research Center, Seattle, Washington
| |
Collapse
|
219
|
Mummudi N, Tibdewal A, Gupta T, Patil V, Prabhash K, Agarwal JP. Tackling brain metastases from lung cancer during the COVID-19 pandemic. Cancer Rep (Hoboken) 2022; 5:e1276. [PMID: 32881412 PMCID: PMC9124513 DOI: 10.1002/cnr2.1276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2020] [Revised: 06/23/2020] [Accepted: 07/07/2020] [Indexed: 12/03/2022] Open
Abstract
Given the enormous strain the COVID-19 pandemic has put on healthcare worldwide, appropriate allocation of resources according to priority is of immense importance. As brain metastases are a common presentation in lung cancer, during the pandemic, it potentially can pose a major management challenge to clinicians. In this article, we outline a pragmatic approach that oncologists should consider while managing these patients. The overarching principle is to deliver best, evidence-based treatment without compromising patient care while ensuring the safety of healthcare workers.
Collapse
Affiliation(s)
- Naveen Mummudi
- Department of Radiation Oncology, Tata Memorial CentreHomi Bhabha National InstituteMumbaiIndia
| | - Anil Tibdewal
- Department of Radiation Oncology, Tata Memorial CentreHomi Bhabha National InstituteMumbaiIndia
| | - Tejpal Gupta
- Department of Radiation Oncology, Tata Memorial CentreHomi Bhabha National InstituteMumbaiIndia
| | - Vijay Patil
- Department of Medical Oncology, Tata Memorial CentreHomi Bhabha National InstituteMumbaiIndia
| | - Kumar Prabhash
- Department of Medical Oncology, Tata Memorial CentreHomi Bhabha National InstituteMumbaiIndia
| | - Jai Prakash Agarwal
- Department of Radiation Oncology, Tata Memorial CentreHomi Bhabha National InstituteMumbaiIndia
| |
Collapse
|
220
|
De‐la‐Rosa‐Martinez D, Aranda‐Audelo M, Martin‐Onraet A, Islas‐Muñoz B, Perez‐Jimenez C, Alatorre‐Fernandez P, Cornejo‐Juarez P, Ruiz‐Garcia E, Zinser‐Peniche P, Nuñez‐Luna L, Meneses‐Garcia A, Herrera‐Gomez A, Vilar‐Compte D. Clinical characteristics and outcomes in a cohort of oncologic patients with COVID-19 during the first year of the pandemic in Mexico. Cancer Med 2022; 11:1827-1836. [PMID: 35166033 PMCID: PMC9041085 DOI: 10.1002/cam4.4582] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2021] [Revised: 12/30/2021] [Accepted: 01/17/2022] [Indexed: 12/15/2022] Open
Abstract
BACKGROUND Literature on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in cancer patients is scarce in Latin America. This population seems to have a higher risk for adverse outcomes. This study aims to correlate clinical characteristics with outcomes in patients with cancer. METHODS We included all patients with cancer and confirmed SARS-CoV-2 infection from April 19 to December 31, 2020, at the Instituto Nacional de Cancerologia, Mexico. Clinical information was obtained from medical and epidemiological records. For the association between variables and hospitalization, invasive mechanical ventilation (IMV), and mortality, univariate and multivariate logistic regression were performed; odds ratios and 95% confidence intervals were calculated. RESULTS Four hundred thirty-three patients were included; 268 (62%) were female, the median age was 55 years. One hundred thirty-five (31%), 131 (30%), and 93 (21%) patients had obesity, hypertension, and diabetes mellitus (DM), respectively. Three hundred forty-one (79%) had solid cancer. One hundred seventy (39%) had advanced cancer. Two hundred (46%) patients were hospitalized. Age (p < 0.01), male gender (p = 0.03), hematological malignancies (HM) (p = 0.04) and advanced cancer (p = 0.03) increased the risk for hospital admission. Forty-five (10%) patients required IMV. Age (p = 0.02); DM (p = 0.04); high C-reactive protein (p < 0.01), and lactate dehydrogenase (p = 0.03) were associated with IMV. Mortality within 30 days after diagnosis was 18% (76 cases). Associated characteristics were age (p = 0.04) and low albumin (p < 0.01). CONCLUSIONS In this study, patients with cancer showed higher mortality, need for hospitalization, and IMV compared with other non-cancer cohorts. We did not find an increased risk in mortality for HM. Although our cohort was younger than others previously reported, age was a strong predictor of adverse outcomes. Variables associated with IMV and death were similar to those previously described in cancer patients with COVID-19.
Collapse
Affiliation(s)
- Daniel De‐la‐Rosa‐Martinez
- Department of Infectious DiseasesInstituto Nacional de CancerologiaMexico CityMexico
- Plan de Estudios Combinados en Medicina (PECEM), Faculty of MedicineUniversidad Nacional Autonoma de MexicoMexico CityMexico
| | - Mercedes Aranda‐Audelo
- Department of Infectious DiseasesInstituto Nacional de CancerologiaMexico CityMexico
- Present address:
Department of Infectious DiseasesHospital General Dr. Manuel Gea GonzalezMexico CityMexico
| | | | - Beda Islas‐Muñoz
- Department of Infectious DiseasesInstituto Nacional de CancerologiaMexico CityMexico
| | | | | | | | - Erika Ruiz‐Garcia
- Translational Medicine Laboratory and Department of Gastrointestinal TumorsInstituto Nacional de CancerologiaMexico CityMexico
| | - Paola Zinser‐Peniche
- Department of Infectious DiseasesInstituto Nacional de CancerologiaMexico CityMexico
| | - Luis Nuñez‐Luna
- Department of Infectious DiseasesInstituto Nacional de CancerologiaMexico CityMexico
| | | | - Angel Herrera‐Gomez
- Division of Surgical OncologyInstituto Nacional de CancerologiaMexico CityMexico
| | - Diana Vilar‐Compte
- Department of Infectious DiseasesInstituto Nacional de CancerologiaMexico CityMexico
| |
Collapse
|
221
|
Chiner-Vives E, Cordovilla-Pérez R, de la Rosa-Carrillo D, García-Clemente M, Izquierdo-Alonso JL, Otero-Candelera R, Pérez-de Llano L, Sellares-Torres J, de Granda-Orive JI. Short and Long-Term Impact of COVID-19 Infection on Previous Respiratory Diseases. Arch Bronconeumol 2022; 58 Suppl 1:39-50. [PMID: 35501222 PMCID: PMC9012323 DOI: 10.1016/j.arbres.2022.03.011] [Citation(s) in RCA: 43] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2022] [Accepted: 03/30/2022] [Indexed: 02/07/2023]
Abstract
On March 11, 2020, the World Health Organization declared Coronavirus Disease 2019 (COVID-19) a pandemic. Till now, it affected 452.4 million (Spain, 11.18 million) persons all over the world with a total of 6.04 million of deaths (Spain, 100,992). It is observed that 75% of hospitalized COVID-19 patients have at least one COVID-19 associated comorbidity. It was shown that people with underlying chronic illnesses are more likely to get it and grow seriously ill. Individuals with COVID-19 who have a past medical history of cardiovascular disorder, cancer, obesity, chronic lung disease, diabetes, or neurological disease had the worst prognosis and are more likely to develop acute respiratory distress syndrome or pneumonia. COVID-19 can affect the respiratory system in a variety of ways and across a spectrum of levels of disease severity, depending on a person's immune system, age and comorbidities. Symptoms can range from mild, such as cough, shortness of breath and fever, to critical disease, including respiratory failure, shock and multi-organ system failure. So, COVID-19 infection can cause overall worsening of these previous respiratory diseases, such as asthma, chronic obstructive pulmonary disease (COPD), interstitial lung disease, etc. This review aims to provide information on the impact of the COVID-19 disease on pre-existing lung comorbidities.
Collapse
Affiliation(s)
- Eusebi Chiner-Vives
- Multidisciplinary Sleep Unit, Respiratory Department, Sant Joan University Hospital, Sant Joan d'Alacant, Alicante, Spain
| | - Rosa Cordovilla-Pérez
- Respiratory Department, Salamanca University Hospital, Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain
| | | | - Marta García-Clemente
- Lung Management Area, HUCA, Institute for Health Research of the Principality of Asturias (ISPA), Oviedo, Asturias, Spain
| | - José Luis Izquierdo-Alonso
- Department of Medicine and Medical Specialties, University of Alcalá, Madrid, Spain; Respiratory Medicine, University Hospital of Guadalajara, Guadalajara, Spain
| | | | - Luis Pérez-de Llano
- Respiratory Department, Lucus Augusti University Hospital, EOXI Lugo, Monforte, CERVO, Lugo, Spain
| | - Jacobo Sellares-Torres
- Interstitial Lung Diseases Working Group, Respiratory Department, Clinic-University Hospital-IDIBAPS, Barcelona, Spain
| | | |
Collapse
|
222
|
Pandey R, Rai D, Tahir MW, Wahab A, Bandyopadhyay D, Lesho E, Laguio-Vila M, Fentanes E, Tariq R, Naidu SS, Aronow WS. Prevalence of comorbidities and symptoms stratified by severity of illness amongst adult patients with COVID-19: a systematic review. Arch Med Sci Atheroscler Dis 2022; 7:e5-e23. [PMID: 35582712 PMCID: PMC9081912 DOI: 10.5114/amsad.2022.115008] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Accepted: 10/27/2021] [Indexed: 02/06/2023] Open
Abstract
Introduction We performed a systematic review of comorbidities and symptoms of adult patients with coronavirus disease 2019 (COVID-19) to evaluate comorbidities, symptoms, and severity. Material and methods We searched databases and extracted comorbidities and symptoms from the included studies. We stratified the similar signs and symptoms in groups and on the basis of severity and compared them with stratified analysis. Individual case reports and case series with < 5 patients were excluded. Results A total of 163 studies with 43,187 patients were included. Mean age was 54.6 years. There were significantly fewer women in the study (43.9% vs. 56.1%, p < 0.0001). Prevalent cardiovascular comorbidities were hypertension (31.9%), obesity (27.9%), hyperlipidemia (26.4%), smoking (18.9%), diabetes mellitus (17.2%), atherosclerotic disease (9.2%) and arrhythmia (5.0%). The most frequently reported constitutional symptoms of COVID-19 were fever (73.9%), fatigue (33.4%), malaise (29.9%), myalgia and/or arthralgia (19.2%), generalized weakness (19.0%), and chills (11.3%). For the cardiovascular system, chest pain and/or tightness were most often reported (19.6%), followed by palpitations (5.2%). Hypertension and diabetes were common in severe disease. Obesity and congestive heart failure were not observed in any non-severe cases. Severe cases compared to non-severe cases more frequently had fever (87.8% vs. 58.5%, p < 0.001), shortness of breath (47.4% vs. 20.6%, p < 0.001), cough (66.8% vs. 62.9%, p < 0.001), sputum production (35.4% vs. 26.5%, p < 0.001) and rhinorrhea (32.2% vs. 7.3%, p < 0.001). Conclusions Hypertension, diabetes, and atherosclerotic diseases are common comorbidities across the world, with obesity as the second most common in the US and more common in men.
Collapse
Affiliation(s)
| | - Devesh Rai
- Department of Internal Medicine, Rochester General Hospital, USA
| | | | - Abdul Wahab
- Department of Internal Medicine, University of Iowa, IA, USA
| | | | - Emil Lesho
- Department of Infectious Disease, Rochester General Hospital, Rochester, NY, USA
| | - Maryrose Laguio-Vila
- Department of Infectious Disease, Rochester General Hospital, Rochester, NY, USA
| | - Emilio Fentanes
- Department of Cardiology, Brigham and Women’s Hospital, MA, USA
| | - Raseen Tariq
- Department of Internal Medicine, Rochester General Hospital, USA
| | - Srihari S. Naidu
- Department of Cardiology, Westchester Medical Center, Valhalla, NY, USA
| | - Wilbert S. Aronow
- Department of Cardiology, Westchester Medical Center, Valhalla, NY, USA
| |
Collapse
|
223
|
Stefan A, Petkovic M, König A, Koch J, Hagemann F, Wuerstlein R, Harbeck N, Mahner S, Kaltofen T. Increased risk for thromboembolic events from combination of a gynecologic malignancy with severe acute respiratory syndrome coronavirus 2 infection: a case report. J Med Case Rep 2022; 16:119. [PMID: 35313981 PMCID: PMC8937821 DOI: 10.1186/s13256-022-03340-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2021] [Accepted: 02/19/2022] [Indexed: 01/08/2023] Open
Abstract
PURPOSE During the severe acute respiratory syndrome coronavirus 2 pandemic, several patient groups are at particular risk. Mortality is higher among cancer patients and may be increased further by thromboembolic events, which are more common in coronavirus 2019 patients according to recent publications. We discuss the association of gynecologic malignancies, Severe acute respiratory syndrome coronavirus 2, and thromboembolism by reporting a case study and summarizing available literature. CASE REPORT A 71-year-old Caucasian patient with ovarian cancer receiving first-line chemotherapy was diagnosed with deep vein thrombosis and pulmonary embolism. Routine screening revealed infection with severe acute respiratory syndrome coronavirus 2 in absence of specific symptoms. After uneventful recovery, oncologic treatment could be continued a few weeks later. METHODS We performed a systematic review of the literature on PubMed following Preferred Reporting Items for Systematic reviews and Meta-Analyses guidelines. The search included articles ahead of print, published between 1 December 2019 and 1 June 2020. Cross-searches were conducted on all relevant articles. RESULTS We identified five articles meeting the defined criteria, including two retrospective studies, a review, a position paper, as well as a letter to the editor. CONCLUSION Cancer patients infected with severe acute respiratory syndrome coronavirus 2 have a relatively poor outcome, which may partially be due to a higher rate of thromboembolic events. Thromboprophylaxis is recommended, and scoring systems are helpful in early detection. In cancer patients with severe acute respiratory syndrome coronavirus 2, individual risk for thromboembolic events should be taken into account when considering interruption versus continuation of antitumoral therapy. However, further data and studies are required.
Collapse
Affiliation(s)
- Alexandra Stefan
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany.
| | - Marija Petkovic
- Department of Medicine IV, University Hospital, LMU Munich, Munich, Germany
| | - Alexander König
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Julian Koch
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Friederike Hagemann
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Rachel Wuerstlein
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Nadia Harbeck
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Sven Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - Till Kaltofen
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| |
Collapse
|
224
|
Alpuim Costa D, Nobre JGG, Fernandes JP, Batista MV, Simas A, Sales C, Gouveia H, Ribeiro LA, Coelho A, Brito M, Inácio M, Cruz A, Mariano M, Savva-Bordalo J, Fernandes R, Oliveira A, Chaves A, Fontes-Sousa M, Sampaio-Alves M, Martins-Branco D, Afonso N. Impact of the COVID-19 Pandemic on Breast Cancer Management in Portugal: A Cross-Sectional Survey-Based Study of Medical Oncologists. Oncol Ther 2022; 10:225-240. [PMID: 35312952 PMCID: PMC8935098 DOI: 10.1007/s40487-022-00191-7] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 02/22/2022] [Indexed: 12/15/2022] Open
Abstract
INTRODUCTION Cancer care providers have faced many challenges in delivering safe care for patients during the COVID-19 pandemic. This cross-sectional survey-based study investigated the impact of the pandemic on clinical practices of Portuguese medical oncologists caring for patients with breast cancer. METHODS An anonymous online survey comprising 42 questions gathered information regarding COVID-19 testing, treatment in (neo)adjuvant and metastatic settings, and other aspects of breast cancer management. Practices before and during the pandemic were compared, and potential differences in outcomes according to respondents' regions, case volumes, and practice type were explored. RESULTS Of 129 respondents, 108 worked in the public health system, giving a representative national picture of the impact of the COVID-19 pandemic on breast cancer management. Seventy-one percent of respondents reported a reduction in visits for new cases of breast cancer, and there was a shift towards increased use of telemedicine. Clinical decision-making was largely unaffected in the most aggressive indications (i.e., triple-negative, HER2-positive, visceral crisis). The use of neoadjuvant therapy increased when access to surgery was difficult, whereas dose-dense regimens decreased, and cyclin-dependent kinase 4/6 inhibitor treatment decreased for less aggressive disease and increased for more aggressive disease. The use of oral formulations and metronomic chemotherapy regimens increased, and clinical trial participation decreased. Some differences by respondents' region and case volume were noted. CONCLUSION Medical oncologists in Portugal implemented many changes during the COVID-19 pandemic, most of which were logical and reasonable responses to the current healthcare emergency; however, the true impact on patient outcomes remains unknown.
Collapse
Affiliation(s)
- Diogo Alpuim Costa
- Breast Cancer Unit, CUF Oncologia, Rua Mário Botas, s/n 1998-018, Lisbon, Portugal. .,NOVA Medical School (NMS), Faculdade de Ciências Médicas (FCM), Campo dos Mártires da Pátria 130, 1169-056, Lisbon, Portugal.
| | | | - João Paulo Fernandes
- Breast Cancer Unit, CUF Oncologia, Rua Mário Botas, s/n 1998-018, Lisbon, Portugal
| | - Marta Vaz Batista
- Medical Oncology Department, Hospital Prof. Doutor Fernando Fonseca (HFF), IC19, 2720-276, Amadora, Portugal
| | - Ana Simas
- Medical Oncology Department, Hospital de Santa Luzia (HSL), Unidade Local Saúde Alto Minho (ULSAM), Estr. de Santa Luzia 50 4900, Viana do Castelo, Portugal
| | - Carolina Sales
- Medical Oncology Department, Hospital Dr. Nélio Mendonça, Hospital Central Do Funchal (HCF), Av. Luís de Camões 6180, 9000-177, Funchal, Madeira, Portugal
| | - Helena Gouveia
- Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Av. Brasília, 1400-038, Lisbon, Portugal
| | - Leonor Abreu Ribeiro
- Breast Cancer Unit, CUF Oncologia, Rua Mário Botas, s/n 1998-018, Lisbon, Portugal.,Medical Oncology Department, Hospital de Santa Maria (HSM), Centro Hospitalar Universitário de Lisboa Norte (CHULN), Av. Prof. Egas Moniz MB, 1649-028, Lisbon, Portugal
| | - Andreia Coelho
- Medical Oncology Department, Hospital de Santo Espírito da Ilha Terceira (HSEIT), Canada do Briado, Canada do Briado, 9700-049, Terceira, Azores, Portugal
| | - Margarida Brito
- Medical Oncology Department, Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), E.P.E., Rua Prof. Lima Basto, Lisbon, Portugal.,Medical Oncology Department, Hospital de São Bernardo (HSB), Centro Hospitalar de Setúbal (CHS), Rua Camilo Castelo Branco, Aptd. 140, Setúbal, Portugal
| | - Mariana Inácio
- Medical Oncology Department, Hospital Do Espírito Santo de Évora (HESE), Largo do Sr. da Pobreza, 7000-811, Évora, Portugal
| | - André Cruz
- Medical Oncology Department, Hospital Particular Do Algarve-Gambelas, Grupo HPA Saúde, Urbanização Casal de Gambelas, Lote 2, 8005-226, Faro, Portugal
| | - Mónica Mariano
- Medical Oncology Department, Instituto Português de Oncologia de Coimbra Francisco Gentil (IPOCFG), E.P.E., Av. Prof. Dr. Bissaya Barreto 98, 3000-075, Coimbra, Portugal
| | - Joana Savva-Bordalo
- Medical Oncology Department, Instituto Português de Oncologia Do Porto Francisco Gentil (IPOPFG), E.P.E., Rua Dr. António Bernardino de Almeida, 4200-072, Oporto, Portugal
| | | | - André Oliveira
- Medical Oncology Department, Hospital Do Divino Espírito Santo (HDES), Av. D. Manuel I, 9500-370, Ponta Delgada, Azores, Portugal
| | - Andreia Chaves
- Breast Cancer Unit, CUF Oncologia, Rua Mário Botas, s/n 1998-018, Lisbon, Portugal.,Medical Oncology Department, Hospital Prof. Doutor Fernando Fonseca (HFF), IC19, 2720-276, Amadora, Portugal
| | - Mário Fontes-Sousa
- Breast Cancer Unit, CUF Oncologia, Rua Mário Botas, s/n 1998-018, Lisbon, Portugal.,Medical Oncology Department, Hospital de São Bernardo (HSB), Centro Hospitalar de Setúbal (CHS), Rua Camilo Castelo Branco, Aptd. 140, Setúbal, Portugal.,Medical Oncology Department, Hospital de São Francisco Xavier (HSFX), Centro Hospitalar de Lisboa Ocidental (CHLO), Estr. Forte do Alto Duque, 1449-005, Lisbon, Portugal
| | - Mafalda Sampaio-Alves
- Faculdade de Medicina, Universidade Do Porto (FMUP), Alameda Prof. Hernâni Monteiro, 4200-319, Oporto, Portugal.,PTSurg-Portuguese Surgical Research Collaborative, Lisbon, Portugal
| | - Diogo Martins-Branco
- Academic Trials Promoting Team, Institut Jules Bordet, l'Université Libre de Bruxelles (ULB), Av. Franklin Roosevelt 50, 1050, Brussels, Belgium
| | - Noémia Afonso
- Medical Oncology Department, Centro Hospitalar Vila Nova de Gaia/Espinho (CHVNG/E), R. Conceição Fernandes S/N, 4434-502, Vila Nova de Gaia, Portugal
| |
Collapse
|
225
|
Alwan NAS, Lami F, Khaleel HA, Alhilfi RA. Impact of COVID-19 on Affected Individuals in Iraq Focusing on Deceased Cancer Patients. JCO Glob Oncol 2022; 8:e2200001. [PMID: 35298294 PMCID: PMC8955141 DOI: 10.1200/go.22.00001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
Mortality because of COVID-19 infections is continuously increasing among the high-risk groups, namely, elderly patients and those with underlying comorbidities including cardiovascular diseases, diabetes, respiratory problems, and cancer. The study aimed to assess the impact of COVID-19 on affected individuals in Iraq, focusing on the characteristics of COVID-19 deceased cases, with special emphasis on cancer as the associated comorbidity. About 70% of patients who died from COVID-19 infection in Iraq had associated comorbidities. Those with history of cancer were younger and spent significantly longer duration in the hospital.![]()
Collapse
Affiliation(s)
- Nada A S Alwan
- National Cancer Research Center, University of Baghdad, Baghdad, Iraq
| | - Faris Lami
- College of Medicine, University of Baghdad, Baghdad, Iraq
| | - Hanan A Khaleel
- Public Health Directorate, Ministry of Health, Baghdad, Iraq
| | | |
Collapse
|
226
|
Gribkova Y, Davis CH, Greenbaum AA, Lu S, Berger AC. Effect of the COVID‐19 pandemic on surgical oncology practice—Results of an SSO survey. J Surg Oncol 2022; 125:1191-1199. [PMID: 35249232 PMCID: PMC9088533 DOI: 10.1002/jso.26839] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2022] [Accepted: 02/21/2022] [Indexed: 11/24/2022]
Abstract
Background and Objectives The COVID‐19 pandemic significantly affected healthcare delivery, shifting focus away from nonurgent care. The aim of this study was to examine the impact of the pandemic on the practice of surgical oncology. Methods A web‐based survey of questions about changes in practice during the COVID‐19 pandemic was approved by the Society of Surgical Oncology (SSO) Research and Executive Committees and sent by SSO to its members. Results A total of 121 SSO members completed the survey, 77.7% (94/121) of whom were based in the United States. Breast surgeons were more likely than their peers to refer patients to neoadjuvant therapy (p = 0.000171). Head and neck surgeons were more likely to refer patients to definitive nonoperative treatment (p = 0.044), while melanoma surgeons were less likely to do so (p = 0.029). In all, 79.2% (95/120) of respondents are currently using telemedicine. US surgeons were more likely to use telemedicine (p = 0.004). Surgeons believed telemedicine is useful for long‐term/surveillance visits (70.2%, 80/114) but inappropriate (50.4%, 57/113) for new patient visits. Conclusion COVID‐19 pandemic resulted in increased use of neoadjuvant therapy, delays in operative procedures, and increased use of telemedicine. Telemedicine is perceived to be most efficacious for long‐term/surveillance visits or postoperative visits.
Collapse
Affiliation(s)
- Yelizaveta Gribkova
- Rutgers Robert Wood Johnson University Medical School New Brunswick New Jersey USA
| | - Catherine H. Davis
- Rutgers Robert Wood Johnson University Medical School New Brunswick New Jersey USA
- Division of Surgical Oncology Rutgers Cancer Institute of New Jersey New Brunswick New Jersey USA
| | - Alissa A. Greenbaum
- Rutgers Robert Wood Johnson University Medical School New Brunswick New Jersey USA
- Division of Surgical Oncology Rutgers Cancer Institute of New Jersey New Brunswick New Jersey USA
| | - Shou‐en Lu
- Department of Biostatistics Rutgers University School of Public Health New Brunswick New Jersey USA
| | - Adam C. Berger
- Rutgers Robert Wood Johnson University Medical School New Brunswick New Jersey USA
- Division of Surgical Oncology Rutgers Cancer Institute of New Jersey New Brunswick New Jersey USA
| |
Collapse
|
227
|
Possible Beneficial Effects of Fresh Pomegranate Juice in SARS-CoV-2 Infection Conditions. J Nutr Metab 2022; 2022:5134560. [PMID: 35287379 PMCID: PMC8917946 DOI: 10.1155/2022/5134560] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/12/2021] [Accepted: 02/18/2022] [Indexed: 11/17/2022] Open
Abstract
Rather than the prophylactic vaccination, any effective synthetic, natural, or nutritional therapy or regimen that may cure or remedy, albeit partially, the complications of SARS-CoV-2 should be highly acknowledged. Here, we reviewed and discussed possible beneficial biological effects of pomegranate juice in such diseased condition of viral infection based on the current published evidence (direct and indirect) and owing to the robust evidence that fresh pomegranate juice is highly rich with unique bioactive compounds that are approved in various occasions to be effective in several chronic diseased conditions. All related references that serve our aim are accessed through available electronic databases, particularly PubMed and Scopus. In summary, there is accepted evidence that pomegranate juice may be beneficial in SARS-CoV-2 infection conditions, especially for patients with the clinical history of chronic diseases such as hypertension, cardiovascular disease, diabetes, and cancer. However, the interventional studies that directly probe and confirm the effectiveness of fresh pomegranate juice in the management of SARS-CoV-2 infection are mandatory.
Collapse
|
228
|
Wu Q, Luo S, Xie X. The impact of anti-tumor approaches on the outcomes of cancer patients with COVID-19: a meta-analysis based on 52 cohorts incorporating 9231 participants. BMC Cancer 2022; 22:241. [PMID: 35246063 PMCID: PMC8895689 DOI: 10.1186/s12885-022-09320-x] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2021] [Accepted: 02/21/2022] [Indexed: 12/14/2022] Open
Abstract
BACKGROUND This study was designed to investigate the impact of anti-tumor approaches (including chemotherapy, targeted therapy, endocrine therapy, immunotherapy, surgery and radiotherapy) on the outcomes of cancer patients with COVID-19. METHODS Electronic databases were searched to identify relevant trials. The primary endpoints were severe disease and death of cancer patients treated with anti-tumor therapy before COVID-19 diagnosis. In addition, stratified analyses were implemented towards various types of anti-tumor therapy and other prognostic factors. Furthermore, odds ratios (ORs) were hereby adopted to measure the outcomes with the corresponding 95% confidence intervals (CIs). RESULTS As indicated in the study consisting of 9231 individuals from 52 cohorts in total, anti-tumor therapy before COVID-19 diagnosis could elevate the risk of death in cancer patients (OR: 1.21, 95%CI: 1.07-1.36, P = 0.0026) and the incidence of severe COVID-19 (OR: 1.19, 95%CI: 1.01-1.40, P = 0.0412). Among various anti-tumor approaches, chemotherapy distinguished to increase the incidence of death (OR = 1.22, 95%CI: 1.08-1.38, P = 0.0013) and severe COVID-19 (OR = 1.10, 95%CI: 1.02-1.18, P = 0.0165) as to cancer patients with COVID-19. Moreover, for cancer patients with COVID-19, surgery and targeted therapy could add to the risk of death (OR = 1.27, 95%CI: 1.00-1.61, P = 0.0472), and the incidence of severe COVID-19 (OR = 1.14, 95%CI: 1.01-1.30, P = 0.0357) respectively. In the subgroup analysis, the incidence of death (OR = 1.17, 95%CI: 1.03-1.34, P = 0.0158) raised in case of chemotherapy adopted for solid tumor with COVID-19. Besides, age, gender, hypertension, COPD, smoking and lung cancer all served as potential prognostic factors for both death and severe disease of cancer patients with COVID-19. CONCLUSIONS Anti-tumor therapy, especially chemotherapy, augmented the risk of severe disease and death for cancer patients with COVID-19, so did surgery for the risk of death and targeted therapy for the incidence of severe COVID-19.
Collapse
Affiliation(s)
- Qing Wu
- Department of Oncology, Molecular Oncology Research Institute, The First Affiliated Hospital of Fujian Medical University, No. 20, Chazhong Road, Fuzhou, 350005, Fujian, China
| | - Shuimei Luo
- Department of Oncology, Molecular Oncology Research Institute, The First Affiliated Hospital of Fujian Medical University, No. 20, Chazhong Road, Fuzhou, 350005, Fujian, China
| | - Xianhe Xie
- Department of Oncology, Molecular Oncology Research Institute, The First Affiliated Hospital of Fujian Medical University, No. 20, Chazhong Road, Fuzhou, 350005, Fujian, China.
- Fujian Key Laboratory of Precision Medicine for Cancer, The First Affiliated Hospital of Fujian Medical University, Fuzhou, 350005, Fujian, China.
| |
Collapse
|
229
|
Safety and Feasibility of Lung Cancer Surgery under the COVID-19 Circumstance. Cancers (Basel) 2022; 14:cancers14051334. [PMID: 35267642 PMCID: PMC8909353 DOI: 10.3390/cancers14051334] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2022] [Accepted: 02/25/2022] [Indexed: 11/29/2022] Open
Abstract
Simple Summary The global coronavirus disease 2019 (COVID-19) pandemic has drastically changed the current practice of medicine worldwide. As more clinical data is collected and processed, we are beginning to have an understanding of which patients are more at risk for severe complications of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections. Preliminary data has shown that patients with lung cancer are disproportionally affected by the current COVID-19 pandemic. Furthermore, studies have shown that lung cancer patients are also significantly more likely to be admitted to the ICU and need mechanical ventilation. A specific subset of patients that are even more at risk for severe COVID-19 are those that require lung cancer surgery. To minimize the risk of SARS-CoV-2 infections in patients undergoing surgery, new treatment guidelines and preventive measures are necessary. In this review, we summarize the latest evidence regarding recommendations for patients undergoing lung cancer surgery in the COVID-19 era. Abstract The current coronavirus disease 2019 (COVID-19) pandemic has forced healthcare providers worldwide to adapt their practices. Our understanding of the effects of COVID-19 has increased exponentially since the beginning of the pandemic. Data from large-scale, international registries has provided more insight regarding risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections and has allowed us to delineate specific subgroups of patients that have higher risks for severe complications. One particular subset of patients that have significantly higher risks of SARS-CoV-2 infection with higher morbidity and mortality rates are those that require surgical treatment for lung cancer. Earlier studies have shown that COVID-19 infections in patients that underwent lung cancer surgery is associated with higher rates of respiratory failure and mortality. However, deferral of cancer treatments is associated with increased mortality as well. This creates difficult situations in which healthcare providers are forced to weigh the benefits of surgical treatment against the possibility of SARS-CoV-2 infections. A number of oncological and surgical organizations have proposed treatment guidelines and recommendations for patients planned for lung cancer surgery. In this review, we summarize the latest data and recommendations for patients undergoing lung cancer surgery in the COVID-19 circumstance.
Collapse
|
230
|
Miyashita N, Nakamori Y, Ogata M, Fukuda N, Yamura A, Ishiura Y, Nomura S. Clinical features of nursing and healthcare-associated pneumonia due to COVID-19. J Infect Chemother 2022; 28:902-906. [PMID: 35317976 PMCID: PMC8934135 DOI: 10.1016/j.jiac.2022.03.010] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/10/2021] [Revised: 02/01/2022] [Accepted: 03/14/2022] [Indexed: 11/30/2022]
Abstract
Introduction The objective of this study was to clarify the clinical differences between nursing and healthcare-associated pneumonia (NHCAP) and community-acquired pneumonia (CAP) due to COVID-19. We also investigated the clinical characteristics to determine whether there is a difference between the variant and non-variant strain in patients with NHCAP due to COVID-19. In addition, we analyzed the clinical outcomes in NHCAP patients with mental disorders who were hospitalized in a medical institution for treatment of mental illness. Methods This study was conducted at five institutions and assessed a total of 836 patients with COVID-19 pneumonia (154 cases were classified as NHCAP and 335 had lineage B.1.1.7.). Results No differences in patient background, clinical findings, disease severity, or outcomes were observed in patients with NHCAP between the non-B.1.1.7 group and B.1.1.7 group. The median age, frequency of comorbid illness, rates of intensive care unit stay, and mortality rate were significantly higher in patients with NHCAP than in those with CAP. Among the patients with NHCAP, the mortality rate was highest at 37.5% in patients with recent cancer treatment, followed by elderly or disabled patients receiving nursing care (24.3%), residents of care facilities (23.0%), patients receiving dialysis (13.6%), and patients in mental hospitals (9.4%). Conclusions Our results demonstrated that there were many differences in the clinical characteristics between NHCAP patients and CAP patients due to COVID-19. It is necessary to consider the prevention and treatment content depending on the presence or absence of applicable criteria for NHCAP.
Collapse
Affiliation(s)
- Naoyuki Miyashita
- First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Japan.
| | - Yasushi Nakamori
- Department of Emergency Medicine, Kansai Medical University Medical Center, Japan
| | - Makoto Ogata
- First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Japan
| | - Naoki Fukuda
- First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Japan
| | - Akihisa Yamura
- First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Japan
| | - Yoshihisa Ishiura
- First Department of Internal Medicine, Division of Respiratory Medicine, Oncology and Allergology, Kansai Medical University Medical Center, Japan
| | - Shosaku Nomura
- First Department of Internal Medicine, Division of Respiratory Medicine, Infectious Disease and Allergology, Kansai Medical University, Japan
| |
Collapse
|
231
|
González-Escamilla M, Pérez-Ibave DC, Burciaga-Flores CH, Ortiz-Murillo VN, Ramírez-Correa GA, Rodríguez-Niño P, Piñeiro-Retif R, Rodríguez-Gutiérrez HF, Alcorta-Nuñez F, González-Guerrero JF, Vidal-Gutiérrez O, Garza-Rodríguez ML. Epidemiological Algorithm for Early Detection of COVID-19 Cases in a Mexican Oncologic Center. Healthcare (Basel) 2022; 10:healthcare10030462. [PMID: 35326940 PMCID: PMC8950794 DOI: 10.3390/healthcare10030462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2022] [Revised: 02/23/2022] [Accepted: 02/25/2022] [Indexed: 02/04/2023] Open
Abstract
An early detection tool for latent COVID-19 infections in oncology staff and patients is essential to prevent outbreaks in a cancer center. (1) Background: In this study, we developed and implemented two early detection tools for the radiotherapy area to identify COVID-19 cases opportunely. (2) Methods: Staff and patients answered a questionnaire (electronic and paper surveys, respectively) with clinical and epidemiological information. The data were collected through two online survey tools: Real-Time Tracking (R-Track) and Summary of Factors (S-Facts). Cut-off values were established according to the algorithm models. SARS-CoV-2 qRT-PCR tests confirmed the positive algorithms individuals. (3) Results: Oncology staff members (n = 142) were tested, and 14% (n = 20) were positives for the R-Track algorithm; 75% (n = 15) were qRT-PCR positive. The S-Facts Algorithm identified 7.75% (n = 11) positive oncology staff members, and 81.82% (n = 9) were qRT-PCR positive. Oncology patients (n = 369) were evaluated, and 1.36% (n = 5) were positive for the Algorithm used. The five patients (100%) were confirmed by qRT-PCR. (4) Conclusions: The proposed early detection tools have proved to be a low-cost and efficient tool in a country where qRT-PCR tests and vaccines are insufficient for the population.
Collapse
Affiliation(s)
- Moisés González-Escamilla
- Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Av. Francisco I. Madero S/N, Mitras Centro, Monterrey 64460, Mexico; (M.G.-E.); (D.C.P.-I.); (C.H.B.-F.); (P.R.-N.); (R.P.-R.); (H.F.R.-G.); (F.A.-N.); (J.F.G.-G.); (O.V.-G.)
| | - Diana Cristina Pérez-Ibave
- Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Av. Francisco I. Madero S/N, Mitras Centro, Monterrey 64460, Mexico; (M.G.-E.); (D.C.P.-I.); (C.H.B.-F.); (P.R.-N.); (R.P.-R.); (H.F.R.-G.); (F.A.-N.); (J.F.G.-G.); (O.V.-G.)
| | - Carlos Horacio Burciaga-Flores
- Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Av. Francisco I. Madero S/N, Mitras Centro, Monterrey 64460, Mexico; (M.G.-E.); (D.C.P.-I.); (C.H.B.-F.); (P.R.-N.); (R.P.-R.); (H.F.R.-G.); (F.A.-N.); (J.F.G.-G.); (O.V.-G.)
| | - Vanessa Natali Ortiz-Murillo
- Facultad de Medicina, Universidad Autónoma de Nuevo León, Av. Francisco I. Madero S/N, Mitras Centro Monterrey, Monterrey 64460, Mexico;
| | - Genaro A. Ramírez-Correa
- Department of Molecular Science, The University of Texas Rio Grande Valley School of Medicine, McAllen, TX 78504, USA;
- Department of Pediatrics, Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
| | - Patricia Rodríguez-Niño
- Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Av. Francisco I. Madero S/N, Mitras Centro, Monterrey 64460, Mexico; (M.G.-E.); (D.C.P.-I.); (C.H.B.-F.); (P.R.-N.); (R.P.-R.); (H.F.R.-G.); (F.A.-N.); (J.F.G.-G.); (O.V.-G.)
| | - Rafael Piñeiro-Retif
- Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Av. Francisco I. Madero S/N, Mitras Centro, Monterrey 64460, Mexico; (M.G.-E.); (D.C.P.-I.); (C.H.B.-F.); (P.R.-N.); (R.P.-R.); (H.F.R.-G.); (F.A.-N.); (J.F.G.-G.); (O.V.-G.)
| | - Hazyadee Frecia Rodríguez-Gutiérrez
- Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Av. Francisco I. Madero S/N, Mitras Centro, Monterrey 64460, Mexico; (M.G.-E.); (D.C.P.-I.); (C.H.B.-F.); (P.R.-N.); (R.P.-R.); (H.F.R.-G.); (F.A.-N.); (J.F.G.-G.); (O.V.-G.)
| | - Fernando Alcorta-Nuñez
- Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Av. Francisco I. Madero S/N, Mitras Centro, Monterrey 64460, Mexico; (M.G.-E.); (D.C.P.-I.); (C.H.B.-F.); (P.R.-N.); (R.P.-R.); (H.F.R.-G.); (F.A.-N.); (J.F.G.-G.); (O.V.-G.)
| | - Juan Francisco González-Guerrero
- Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Av. Francisco I. Madero S/N, Mitras Centro, Monterrey 64460, Mexico; (M.G.-E.); (D.C.P.-I.); (C.H.B.-F.); (P.R.-N.); (R.P.-R.); (H.F.R.-G.); (F.A.-N.); (J.F.G.-G.); (O.V.-G.)
| | - Oscar Vidal-Gutiérrez
- Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Av. Francisco I. Madero S/N, Mitras Centro, Monterrey 64460, Mexico; (M.G.-E.); (D.C.P.-I.); (C.H.B.-F.); (P.R.-N.); (R.P.-R.); (H.F.R.-G.); (F.A.-N.); (J.F.G.-G.); (O.V.-G.)
| | - María Lourdes Garza-Rodríguez
- Centro Universitario Contra el Cáncer, Universidad Autónoma de Nuevo León, Hospital Universitario “Dr. José Eleuterio González”, Av. Francisco I. Madero S/N, Mitras Centro, Monterrey 64460, Mexico; (M.G.-E.); (D.C.P.-I.); (C.H.B.-F.); (P.R.-N.); (R.P.-R.); (H.F.R.-G.); (F.A.-N.); (J.F.G.-G.); (O.V.-G.)
- Department of Molecular Science, The University of Texas Rio Grande Valley School of Medicine, McAllen, TX 78504, USA;
- Correspondence: ; Tel.: +52-811-801-4350
| |
Collapse
|
232
|
Morais S, Antunes L, Rodrigues J, Fontes F, Bento MJ, Lunet N. The impact of the coronavirus disease 2019 pandemic on the diagnosis and treatment of cancer in Northern Portugal. Eur J Cancer Prev 2022; 31:204-214. [PMID: 34267109 PMCID: PMC8808756 DOI: 10.1097/cej.0000000000000686] [Citation(s) in RCA: 19] [Impact Index Per Article: 6.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2021] [Accepted: 02/07/2021] [Indexed: 01/09/2023]
Abstract
OBJECTIVES The coronavirus disease 2019 (COVID-19) pandemic has affected the availability of healthcare resources, and adjustments to cancer care have been necessary considering the risk of morbidity by COVID-19 and of cancer progression. This study aims to quantify the impact of the COVID-19 pandemic on the care of patients with cancer by comparing a period of 4 months after the outbreak began (2 March 2020) with an equal period from 2019. METHODS Cancer cases of the esophagus, stomach, colon and rectum, pancreas, lung, skin-melanoma, breast, cervix, prostate, non-Hodgkin lymphoma, and leukemia from the Portuguese Oncology Institute of Porto, and diagnosed between 2 March and 1 July 2019 (before COVID-19) and 2020 (after COVID-19) were identified. Those with the first treatment outside the Portuguese Oncology Institute of Porto were excluded. Sociodemographic, clinical and treatment characteristics were obtained from the cancer registry database and clinical files. RESULTS The absolute number of new cancer cases decreased nearly 40% after the COVID-19 pandemic (from 1430 to 866). The largest decreases were observed for cervical (-74.3%) and prostate (-71.7%) cancers. Cases were more often diagnosed at more advanced stages in 2020 (P = 0.001), and the proportion of patients not starting any treatment until 1 July was just under 20% in 2019 and nearly 40% in 2020. The median times from symptoms onset, first medical exam and first appointment to diagnosis, and from diagnosis to first appointment, multidisciplinary tumor board meeting and first treatment were shorter after COVID-19. CONCLUSIONS There was a notable overall decrease in cancer diagnoses after COVID-19, with changes in the characteristics of incident cases.
Collapse
Affiliation(s)
- Samantha Morais
- EPIUnit, Instituto de Saúde Pública, Universidade do Porto, Rua das Taipas n°135
- Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, Alameda Professor Hernâni Monteiro
| | - Luís Antunes
- Grupo de Epidemiologia do Cancro, Centro de Investigação do Instituto Português de Oncologia do Porto, Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida
| | - Jéssica Rodrigues
- Grupo de Epidemiologia do Cancro, Centro de Investigação do Instituto Português de Oncologia do Porto, Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida
| | - Filipa Fontes
- EPIUnit, Instituto de Saúde Pública, Universidade do Porto, Rua das Taipas n°135
- Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, Alameda Professor Hernâni Monteiro
- Serviço de Imagem, Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida
| | - Maria José Bento
- Grupo de Epidemiologia do Cancro, Centro de Investigação do Instituto Português de Oncologia do Porto, Instituto Português de Oncologia do Porto, Rua Dr. António Bernardino de Almeida
- Departamento de Estudos de Populações, Instituto de Ciências Biomédicas Abel Salazar da Universidade do Porto, Rua Jorge de Viterbo Ferreira 228, Porto, Portugal
| | - Nuno Lunet
- EPIUnit, Instituto de Saúde Pública, Universidade do Porto, Rua das Taipas n°135
- Departamento de Ciências da Saúde Pública e Forenses e Educação Médica, Faculdade de Medicina da Universidade do Porto, Alameda Professor Hernâni Monteiro
| |
Collapse
|
233
|
Valdiviezo N, Alcarraz C, Castro D, Salas R, Begazo-Mollo V, Galvez-Villanueva M, Medina Aguirre L, Garcia-León E, Quispe-Santivañez I, Cornejo-Raymundo C, Paz-Cornejo E, Sanchez-Vilela L, Bermudez-Alfaro V, Vargas-Nina JC, Pérez-Ramos C, Meza-Hoces A, Valdez Barreto PR, Huaringa-Leiva R, Muro-Cieza J, Aguilar-Vásquez V, Cuenca EY, Neciosup-Delgado S, Poma-Nieto N, Chavez-Gavino S, Fernandez-Rosas L, Araujo JM, Payet E, Gomez HL. Oncological Care During First Peruvian National Emergency COVID-19 Pandemic: A Multicentric Descriptive Study. Cancer Manag Res 2022; 14:1075-1085. [PMID: 35300062 PMCID: PMC8922040 DOI: 10.2147/cmar.s350038] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2021] [Accepted: 02/15/2022] [Indexed: 12/24/2022] Open
Affiliation(s)
- Natalia Valdiviezo
- Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima, 15038, Peru
- Correspondence: Natalia Valdiviezo, Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Av. Angamos 2520, Surquillo, Lima, 15038, Peru, Tel +51 992825055, Email
| | - Cindy Alcarraz
- Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima, 15038, Peru
- Escuela Profesional de Medicina Humana, Universidad Privada San Juan Bautista, Lima, Perú
| | - Denisse Castro
- Departamento de Oncología Médica, Hospital Nacional Edgardo Rebagliati Martins, Lima, 15072, Peru
- Centro de Investigación de Medicina de Precisión, Universidad de San Martin de Porres, Lima, 15024, Peru
| | - Renzo Salas
- Departamento de Oncología Médica, Hospital Nacional Edgardo Rebagliati Martins, Lima, 15072, Peru
| | - Victor Begazo-Mollo
- Departamento de Medicina Oncológica, Instituto Regional de Enfermedades Neoplásicas Sur, Arequipa, Perú
| | - Marco Galvez-Villanueva
- Departamento de Medicina Oncológica, Instituto Regional de Enfermedades Neoplásicas Norte, La Libertad, Perú
| | - Luz Medina Aguirre
- Departamento de Medicina Oncológica, Hospital Goyeneche, Arequipa, 04600, Perú
| | - Elica Garcia-León
- Departamento de Medicina Oncológica, Hospital Regional de Lambayeque, Lambayeque, 14001, Perú
| | | | | | - Eduardo Paz-Cornejo
- Departamento de Medicina Oncológica, Hospital Nacional Alberto Sabogal Sologuren, Lima, Peru
| | - Luis Sanchez-Vilela
- Departamento de Medicina Oncológica, Hospital de Apoyo II Santa Rosa, Piura, Peru
| | - Vanessa Bermudez-Alfaro
- Departamento de Medicina Oncológica, Hospital Nacional Guillermo Almenara Irigoyen, Lima, 15033, Peru
| | | | - Carlos Pérez-Ramos
- Departamento de Medicina Oncológica, Hospital María Auxiliadora, Lima, Peru
| | - Andrea Meza-Hoces
- Departamento de Medicina Oncológica, Hospital II E de Lamas, San Martin, Peru
| | - Paolo R Valdez Barreto
- Departamento de Medicina Oncológica, Hospital de Alta complejidad Virgen de la Puerta, La Libertad, Peru
| | | | - Johanny Muro-Cieza
- Departamento de Medicina Oncológica, Hospital Regional Docente de Cajamarca, Cajamarca, Peru
| | - Valeria Aguilar-Vásquez
- Departamento de Promoción de la Salud, Prevención y Control del Cáncer, Instituto Regional de Enfermedades Neoplásicas Norte, La Libertad, Perú
| | - Eduardo Yache Cuenca
- Departamento de Epidemiología, Instituto Regional de Enfermedades Neoplásicas Norte, La Libertad, Perú
| | - Silvia Neciosup-Delgado
- Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima, 15038, Peru
| | - Nathaly Poma-Nieto
- Departamento de Medicina Oncológica, Hospital Nacional Daniel Alcides Carrión, Lima, Perú
| | - Sheyla Chavez-Gavino
- Departamento de Medicina Oncológica, Hospital Regional Eleazar Guzmán Barrón, Ancash, Perú
| | - Lenin Fernandez-Rosas
- Departamento de Cirugía Oncológica, Hospital Regional Eleazar Guzmán Barrón, Ancash, Perú
| | - Jhajaira M Araujo
- Escuela Profesional de Medicina Humana, Universidad Privada San Juan Bautista, Lima, Perú
| | - Eduardo Payet
- Jefatura Institucional, Instituto Nacional de Enfermedades Neoplásicas, Lima, 15038, Peru
| | - Henry L Gomez
- Departamento de Medicina Oncológica, Instituto Nacional de Enfermedades Neoplásicas, Lima, 15038, Peru
| |
Collapse
|
234
|
Bourdoncle S, Eche T, McGale J, Yiu K, Partouche E, Yeh R, Ammari S, Rousseau H, Dercle L, Mokrane FZ. Investigating of the role of CT scan for cancer patients during the first wave of COVID-19 pandemic. RESEARCH IN DIAGNOSTIC AND INTERVENTIONAL IMAGING 2022. [PMID: 37520011 PMCID: PMC8970534 DOI: 10.1016/j.redii.2022.100004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Introduction Amidst this current COVID-19 pandemic, we undertook this systematic review to determine the role of medical imaging, with a special emphasis on computed tomography (CT), on guiding the care and management of oncologic patients. Material and Methods Study selection focused on articles from 01/02/2020 to 04/23/2020. After removal of irrelevant articles, all systematic or non-systematic reviews, comments, correspondence, editorials, guidelines and meta-analysis and case reports with less than 5 patients were also excluded. Full-text articles of eligible publications were reviewed to select all imaging-based publications, and the existence or not of an oncologic population was reported for each publication. Two independent reviewers collected the following information: ( 1) General publication data; (2) Study design characteristics; (3) Demographic, clinical and pathological variables with percentage of cancer patients if available; (4) Imaging performances. The sensitivity and specificity of chest CT (C-CT) were pooled separately using a random-effects model. The positive predictive value (PPV) and negative predictive value (NPV) of C-CT as a test was estimated for a wide range of disease prevalence rates. Results A total of 106 publications were fully reviewed. Among them, 96 were identified to have extractable data for a two-by-two contingency table for CT performance. At the end, 53 studies (including 6 that used two different populations) were included in diagnosis accuracy analysis (N = 59). We identified 53 studies totaling 11,352 patients for whom the sensitivity (95CI) was 0.886 (0.880; 0.894), while specificity remained low: in 93% of cases (55/59), specificity was ≤ 0.5. Among all the 106 reviewed studies, only 7 studies included oncologic patients and were included in the final analysis for C-CT performances. The percentage of patients with cancer in these studies was 0.3% (34/11352 patients), lower than the global prevalence of cancer. Among all these studies, only 1 (0.9%, 1/106) reported performance specifically in a cohort of cancer patients, but it however only reported true positives. Discussion There is a concerning lack of COVID-19 studies involving oncologic patients, showing there is a real need for further investigation and evaluation of the performance of the different medical imaging modalities in this specific patient population.
Collapse
|
235
|
Hurt B, Rubel MA, Masutani EM, Jacobs K, Hahn L, Horowitz M, Kligerman S, Hsiao A. Radiologist-supervised Transfer Learning: Improving Radiographic Localization of Pneumonia and Prognostication of Patients With COVID-19. J Thorac Imaging 2022; 37:90-99. [PMID: 34710891 PMCID: PMC8863580 DOI: 10.1097/rti.0000000000000618] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE To assess the potential of a transfer learning strategy leveraging radiologist supervision to enhance convolutional neural network-based (CNN) localization of pneumonia on radiographs and to further assess the prognostic value of CNN severity quantification on patients evaluated for COVID-19 pneumonia, for whom severity on the presenting radiograph is a known predictor of mortality and intubation. MATERIALS AND METHODS We obtained an initial CNN previously trained to localize pneumonia along with 25,684 radiographs used for its training. We additionally curated 1466 radiographs from patients who had a computed tomography (CT) performed on the same day. Regional likelihoods of pneumonia were then annotated by cardiothoracic radiologists, referencing these CTs. Combining data, a preexisting CNN was fine-tuned using transfer learning. Whole-image and regional performance of the updated CNN was assessed using receiver-operating characteristic area under the curve and Dice. Finally, the value of CNN measurements was assessed with survival analysis on 203 patients with COVID-19 and compared against modified radiographic assessment of lung edema (mRALE) score. RESULTS Pneumonia detection area under the curve improved on both internal (0.756 to 0.841) and external (0.864 to 0.876) validation data. Dice overlap also improved, particularly in the lung bases (R: 0.121 to 0.433, L: 0.111 to 0.486). There was strong correlation between radiologist mRALE score and CNN fractional area of involvement (ρ=0.85). Survival analysis showed similar, strong prognostic ability of the CNN and mRALE for mortality, likelihood of intubation, and duration of hospitalization among patients with COVID-19. CONCLUSIONS Radiologist-supervised transfer learning can enhance the ability of CNNs to localize and quantify the severity of disease. Closed-loop systems incorporating radiologists may be beneficial for continued improvement of artificial intelligence algorithms.
Collapse
Affiliation(s)
- Brian Hurt
- Department of Radiology, University of California San Diego School of Medicine
| | - Meagan A Rubel
- Department of Radiology, University of California San Diego School of Medicine
| | - Evan M Masutani
- Department of Radiology, University of California San Diego School of Medicine
- Department of Bioengineering, University of California, San Diego, San Diego, CA
| | - Kathleen Jacobs
- Department of Radiology, University of California San Diego School of Medicine
| | - Lewis Hahn
- Department of Radiology, University of California San Diego School of Medicine
| | - Michael Horowitz
- Department of Radiology, University of California San Diego School of Medicine
| | - Seth Kligerman
- Department of Radiology, University of California San Diego School of Medicine
| | - Albert Hsiao
- Department of Radiology, University of California San Diego School of Medicine
| |
Collapse
|
236
|
Checcucci E, Piramide F, Pecoraro A, Amparore D, Campi R, Fiori C, Elhage O, Kotecha P, Vyakarnam A, Serni S, Dasgupta P, Porpiglia F. The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans. Panminerva Med 2022; 64:72-79. [PMID: 32456404 DOI: 10.23736/s0031-0808.20.03958-0] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
Abstract
INTRODUCTION Since December 2019, there has been an outbreak of a novel beta-Coronavirus (SARS-CoV-2) in Wuhan, China. On March 11, 2020, the World Health Organization (WHO) declared COVID-19 as a pandemic, with over 118,000 cases in more than 110 countries around the world. In response to the global Coronavirus disease 2019 (COVID-19) emergency, clinical trial research assessing the efficacy and safety of experimental vaccines to prevent COVID-19 are emerging at an unprecedented rate. The aim of this systematic review was to summarize the preliminary experiences and ongoing clinical trials of the major candidates and challenges of the vaccine strategies in humans. EVIDENCE ACQUISITION After a-priori protocol registration with PROSPERO (181483), systematic research of the published literature was conducted on April 24, 2020, using Medline (via PubMed), Embase (via Ovid), and WHO databases. Moreover, to explore the more recent literature we also searched the preprint server medRxiv. Finally, we scrutinized the Cochrane COVID-19 study register and the COVID-19 section of ClinicalTrials.gov database to identify relevant ongoing clinical trials. Thereafter we selected the articles according to the PRISMA Guidelines. Animal or in-vitro experimental studies were excluded. Moreover editorials, commentaries, abstracts, reviews, book chapters, and articles not in English were not included. EVIDENCE SYNTHESIS Our search identified 1359 published papers, 478 preprint articles and 367 ongoing clinical trials. Finally, only ten ongoing clinical trials met the inclusion criteria. Specifically, seven developed vaccines for the S protein of SARS-CoV-2 and three clinical trials assessed the protective role of BCG vaccine against COVID-19. The first group included phase I/II trials with different types of molecules (DNA or mRNA vaccine, bacterial plasmid or viral vectors), the latter were phase III/IV trials designed on the basis of a heterologous lymphocyte activation by the BCG vaccine. CONCLUSIONS This new disease is pushing the scientific community to develop swiftly a safe and effective vaccine. Notwithstanding the limitations of our analysis, given by the absence of available results, we try to provide a comprehensive view of the ongoing clinical trials in humans. Our analysis reveals a worldwide effort of both scientists and enterprises to achieve one of the most challenging goals of our century.
Collapse
Affiliation(s)
- Enrico Checcucci
- School of Medicine, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy -
| | - Federico Piramide
- School of Medicine, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy
| | - Angela Pecoraro
- School of Medicine, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy
| | - Daniele Amparore
- School of Medicine, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy
| | - Riccardo Campi
- Unit of Urological Robotic Surgery and Renal Transplantation, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy
| | - Cristian Fiori
- School of Medicine, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy
| | - Oussama Elhage
- King's College London, Faculty of Life Sciences and Medicine, Guy's Hospital, London, UK
| | - Pinky Kotecha
- King's College London, Faculty of Life Sciences and Medicine, Guy's Hospital, London, UK
| | - Annapurna Vyakarnam
- King's College London, Faculty of Life Sciences and Medicine, Guy's Hospital, London, UK
| | - Sergio Serni
- Unit of Urological Robotic Surgery and Renal Transplantation, Department of Experimental and Clinical Medicine, Careggi Hospital, University of Florence, Florence, Italy
| | - Prokar Dasgupta
- King's College London, Faculty of Life Sciences and Medicine, Guy's Hospital, London, UK
| | - Francesco Porpiglia
- School of Medicine, Department of Oncology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Turin, Italy
| |
Collapse
|
237
|
Bhatia RK, Lichter KE, Gurram L, MacDuffie E, Lombe D, Sarria GR, Grover S. Gynecologic radiation therapy in low and middle income countries during the COVID-19 pandemic. Int J Gynecol Cancer 2022; 32:446-450. [PMID: 35256435 PMCID: PMC9997715 DOI: 10.1136/ijgc-2021-003039] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2021] [Accepted: 12/14/2021] [Indexed: 02/04/2023] Open
Abstract
The COVID-19 pandemic has forever affected healthcare and posed an incredible challenge to our society to care for our sick. Patients with cancer were found early on to have higher rates of complications with COVID-19. Radiation therapy is an integral part of treatment for many types of gynecologic cancer and adaptation on its utilization during the pandemic varied across the globe. In this review, we detail certain guidelines for the use of radiation in gynecologic cancers during the pandemic as well as real world accounts of how different countries adapted to these guidelines or created their own based on individualized resources, staffing, government restrictions, and societal norms. Critically, this review demonstrates the breadth of fractionation schemes and technologies used when resources were limited but highlights the importance of long term follow-up for many of our patients during this time.
Collapse
Affiliation(s)
- Rohini K Bhatia
- Department of Radiation Oncology and Molecular Sciences, Johns Hopkins School of Medicine, Baltimore, Maryland, USA
| | - Katie E Lichter
- Department of Radiation Oncology, University of California San Francisco, San Francisco, California, USA
| | - Lavanya Gurram
- Radiation Oncology, Tata Memorial Hospital, Mumbai, Maharashtra, India
| | - Emily MacDuffie
- Department of Radiation Oncology, University of Pennsylvania, Philadelphia, Pennsylvania, USA
| | | | - Gustavo R Sarria
- Department of Radiation Oncology, University Hospital Bonn, Bonn, Nordrhein-Westfalen, Germany
| | - Surbhi Grover
- Department of Radiation Oncology, Botswana-University of Pennsylvania Partnership, Philadelphia, Pennsylvania, USA
- University of Pennsylvania, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA
| |
Collapse
|
238
|
Buyukkor M, Tay F, Ates O. Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib. J Oncol Pharm Pract 2022; 28:1906-1909. [DOI: 10.1177/10781552221083321] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Introduction The SARS-COV-2 (COVID-19) pandemic is challenging the management of cancer patients. In this article, we present two patients diagnosed with anaplastic lymphoma kinase (ALK) + non-small cell lung adenocarcinoma (NSCL CA), infected with COVID-19, who had a previous multi-line therapy with Brigatinib and Lorlatinib, and received Favipiravir for their current infection. Case reports A 58-year-old man and a 65-year-old woman were diagnosed as ALK ( + ) NSCL CA. Both patients received tyrosine kinase inhibitors (TKI) for lung cancer when diagnosed with COVID-19. No adverse effects were observed with the concurrent use of Favipiravir, an antiviral drug currently used for COVID-19 and TKI. Management and outcome Considering the pharmacokinetic effects of favipiravir and the ALK inhibitor TKI's used on our cases (Brigatinib-Lorlatinib), the concurrent use of these drugs was safe and prevented the delay in the primary treatment of the malignancy of our patients. Discussion To our knowledge, these are the only reported cases diagnosed as ALK ( + ) NSCL CA who received favipiravir because of COVID-19 while using TKI, and both patients recovered completely without any side effects.
Collapse
Affiliation(s)
- Mustafa Buyukkor
- Medical Oncology, Ankara Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Fatih Tay
- Medical Oncology, Ankara Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| | - Ozturk Ates
- Medical Oncology, Ankara Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital, Ankara, Turkey
| |
Collapse
|
239
|
High Dose Intravenous Vitamin C as Adjunctive Therapy for COVID-19 Patients with Cancer: Two Cases. Life (Basel) 2022; 12:life12030335. [PMID: 35330086 PMCID: PMC8953706 DOI: 10.3390/life12030335] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2021] [Revised: 02/09/2022] [Accepted: 02/11/2022] [Indexed: 12/15/2022] Open
Abstract
Background: Related to the SARS-CoV-2 pandemic leading to COVID-19 illness, patients with cancer comorbidity are known to have a higher risk of developing severe viral-related events, including death. To date, there are few treatments with proven efficacy for COVID-19. Vitamin C administered intravenously (IVC) has been extensively investigated in cancer treatment with a known safety profile and has been proposed to play a role in managing COVID-19. IVC was used to treat COVID-19 patients in hospitals in China, USA, and Europe with reported benefits. We report here unexpected beneficial results from the use of IVC in two severely ill oncology patients with documented COVID-19 lung disease. Case Report: two oncology patients were diagnosed with SARS-CoV-2 infection. Prior to receiving IVC, lung infiltrates and systemic inflammation in both patients were progressing despite multiple anti-viral, antibiotic, and anti-inflammatory treatments with intensive supportive care. Both patients subsequently received 12 g of IVC delivered intravenously over 30 min, given 2 times daily for 7 days. Serial SARS-CoV-2 nucleic acid tests showed that the viral load was negative only after the 7-day IVC treatment. In both patients after receiving IVC infusions, imaging by chest CT or X-ray showed improving lung infiltrates. There were reductions in systematic inflammation by high-sensitivity C-reactive protein (hsCRP), and Interleukin-6 (IL-6) testing. No adverse events were observed related to IVC treatment. Conclusion: the use of high-dose IVC demonstrated unexpected clinical benefits in treating COVID-19 in two cancer patients presenting with complicated severe comorbidities where an unfavorable prognosis was anticipated.
Collapse
|
240
|
Fernandes G, Paixão P, Brum L, Padrão T, Correia J, Albuquerque J, Pulido C, Nave M, Timóteo T, Rodrigues T, Costa F, Passos-Coelho JL. SARS-CoV-2 Antibody Seroprevalence in Patients With Cancer on Systemic Antineoplastic Treatment in the First Wave of the COVID-19 Pandemic in Portugal. Cureus 2022; 14:e22428. [PMID: 35273890 PMCID: PMC8901131 DOI: 10.7759/cureus.22428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 02/21/2022] [Indexed: 11/05/2022] Open
|
241
|
Healthcare Disparities and Outcomes of Cancer Patients in a Community Setting from a COVID-19 Epicenter. Curr Oncol 2022; 29:1150-1162. [PMID: 35200597 PMCID: PMC8870882 DOI: 10.3390/curroncol29020098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 02/03/2022] [Accepted: 02/10/2022] [Indexed: 01/08/2023] Open
Abstract
There have been numerous studies demonstrating how cancer patients are at an increased risk of mortality. Within New York City, our community hospital emerged as an epicenter of the first wave of the pandemic in the spring of 2020 and serves a unique population that is predominately uninsured, of a lower income, and racially/ethnically diverse. In this single institution retrospective study, the authors seek to investigate COVID-19 diagnosis, severity and mortality in patients with an active cancer diagnosis. Demographic, clinical characteristics, treatment, SARS-CoV-2 laboratory results, and outcomes were evaluated. In our community hospital during the first wave of the COVID-19 pandemic in the United States, patients with active cancer diagnosis appear to be at increased risk for mortality (30%) and severe events (50%) due to the SARS-CoV-2 infection compared to the general population. A higher proportion of active cancer patients with Medicaid insurance, Hispanic ethnicity, other race, and male sex had complications and death from COVID-19 infection. The pandemic has highlighted the health inequities that exist in vulnerable patient populations and underserved communities such as ours.
Collapse
|
242
|
Alessio L, Pisaturo M, Russo A, Onorato L, Starace M, Atripaldi L, Coppola N. Different Clinical Outcomes of COVID-19 in Two Healthcare Workers Vaccinated with BNT162b2 Vaccine, Infected with the Same Viral Variant but with Different Predisposing Conditions for the Progression of the Disease. Vaccines (Basel) 2022; 10:298. [PMID: 35214756 PMCID: PMC8877805 DOI: 10.3390/vaccines10020298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/01/2022] [Revised: 02/01/2022] [Accepted: 02/11/2022] [Indexed: 02/06/2023] Open
Abstract
Safe and effective vaccines are available to face the global threat of the COVID-19 pandemic. In this article, we report on the clinical cases of two healthcare workers vaccinated with two doses of BNT162b2 vaccine who were infected by the same viral clade but had different clinical outcomes.
Collapse
Affiliation(s)
- Loredana Alessio
- Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania L. Vanvitelli, 80138 Naples, Italy; (L.A.); (M.P.); (A.R.); (L.O.); (M.S.)
| | - Mariantonietta Pisaturo
- Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania L. Vanvitelli, 80138 Naples, Italy; (L.A.); (M.P.); (A.R.); (L.O.); (M.S.)
| | - Antonio Russo
- Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania L. Vanvitelli, 80138 Naples, Italy; (L.A.); (M.P.); (A.R.); (L.O.); (M.S.)
| | - Lorenzo Onorato
- Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania L. Vanvitelli, 80138 Naples, Italy; (L.A.); (M.P.); (A.R.); (L.O.); (M.S.)
| | - Mario Starace
- Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania L. Vanvitelli, 80138 Naples, Italy; (L.A.); (M.P.); (A.R.); (L.O.); (M.S.)
| | - Luigi Atripaldi
- U.O.C. di Patologia Clinica Ospedale D. Cotugno, Azienda Sanitaria Ospedali dei Colli, 80131 Naples, Italy;
| | - Nicola Coppola
- Department of Mental Health and Public Medicine, Section of Infectious Diseases, University of Campania L. Vanvitelli, 80138 Naples, Italy; (L.A.); (M.P.); (A.R.); (L.O.); (M.S.)
| |
Collapse
|
243
|
Psychosocial Implications of COVID-19 on Head and Neck Cancer. Curr Oncol 2022; 29:1062-1068. [PMID: 35200589 PMCID: PMC8870852 DOI: 10.3390/curroncol29020090] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2021] [Revised: 02/03/2022] [Accepted: 02/10/2022] [Indexed: 11/17/2022] Open
Abstract
The COVID-19 pandemic has fundamentally changed healthcare access, delivery, and treatment paradigms throughout oncology. Patients with head and neck cancer comprise an especially vulnerable population due to the nature of their disease and the transmission mechanism of the SARS-CoV-2 virus. The consequences of triage decisions and delays in care have serious psychosocial implications for patients. The development of structured psychosocial support programs, coupled with clear and consistent communication from treating physicians, can help mitigate perceptions of abandonment and distress that may accompany delays in care. As the unpredictability of the pandemic’s course continues to burden both providers and patients, we must be proactive in addressing the psychosocial implications of these delays in care.
Collapse
|
244
|
Han S, Zhuang Q, Chiang J, Tan SH, Chua GWY, Xie C, Chua MLK, Soon YY, Yang VS. Impact of cancer diagnoses on the outcomes of patients with COVID-19: a systematic review and meta-analysis. BMJ Open 2022; 12:e044661. [PMID: 35131810 PMCID: PMC8822543 DOI: 10.1136/bmjopen-2020-044661] [Citation(s) in RCA: 26] [Impact Index Per Article: 8.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/08/2023] Open
Abstract
BACKGROUND The COVID-19 has caused significant mortality and morbidity across the globe. Patients with cancer are especially vulnerable given their immunocompromised state. We aimed to determine the proportion of COVID-19 patients with cancer, their severity and mortality outcomes through a systematic review and meta-analysis (MA). METHODS Systematic review was performed through online databases, PubMed, Medline and Google Scholar, with keywords listed in the Methods section (1 November 2019-31 December 2020). Studies with clinical outcomes of at least 10 COVID-19 patients and at least one with a diagnosis of cancer were included. The studies for MA were assessed with PRISMA guidelines and appraised with Newcastle-Ottawa Scale. The data were pooled using a random-effects model using STATA software. The main outcomes were planned before data collection, including proportion of patients with cancer among COVID-19 populations, relative risk (RR) of severe outcomes and death of patients with cancer compared with general COVID-19 patients. RESULTS We identified 57 case series (63 413 patients), with 230 patients with cancer with individual patient data (IPD). We found that the pooled proportion of cancer among COVID-19 patients was 0.04 (95% CI 0.03 to 0.05, I2=97.69%, p<0.001). The pooled RR of death was 1.44 (95% CI 1.19 to 1.76) between patients with cancer and the general population with COVID-19 infection. The pooled RR of severe outcome was 1.49 (95% CI 1.18 to 1.87) between cancer and general COVID-19 patients. The presence of lung cancer and stage IV cancer did not result in significantly increased RR of severe outcome. Among the available IPD, only age and gender were associated with severe outcomes. CONCLUSION Patients with cancer were at a higher risk of severe and death outcomes from COVID-19 infection as compared with general COVID-19 populations. Limitations of this study include publication bias. A collaborative effort is required for a more complete database.
Collapse
Affiliation(s)
- Shuting Han
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore
| | - Qingyuan Zhuang
- Division of Supportive and Palliative Care, National Cancer Centre Singapore, Singapore
| | - Jianbang Chiang
- Division of Medical Oncology, National Cancer Centre Singapore, Singapore
| | - Sze Huey Tan
- Biostatistics and Epidemiology Unit, National Cancer Centre Singapore, Singapore
| | - Gail Wan Ying Chua
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore
| | - Conghua Xie
- Department of Radiation and Medical Oncology, Wuhan University Zhongnan Hospital, Wuhan, Hubei, China
| | - Melvin L K Chua
- Division of Radiation Oncology, National Cancer Centre Singapore, Singapore
| | - Yu Yang Soon
- Department of Radiation Oncology, National University Cancer Institute, Singapore
| | | |
Collapse
|
245
|
Pisapia P, Pepe F, Gristina V, La Mantia M, Francomano V, Russo G, Iaccarino A, Galvano A. A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic. MEDIASTINUM (HONG KONG, CHINA) 2022; 5:27. [PMID: 35118332 PMCID: PMC8794438 DOI: 10.21037/med-21-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/25/2021] [Accepted: 07/13/2021] [Indexed: 12/11/2022]
Abstract
Objective In this review, we evaluate the role of liquid biopsy in managing lung cancer patients during the still ongoing coronavirus disease 2019 (COVID-19) healthcare emergency. Background The novel influenza coronavirus (severe acute respiratory syndrome coronavirus or SARS-CoV-2) has upended several aspects of our lives, including medical activities. In this setting, many routine cancer diagnostic and therapeutic procedures have been suspended, leading to delays in diagnosis, treatments, and, ultimately, increases in cancer mortality rates. Equally drastic has been the impact of COVID-19 on clinical trials, many of which have been stalled or have never begun. This has left many patients who were hoping to receive innovative treatments in a limbo. Although, as of today, the introduction of drastic security measures has been crucially important to contain the pandemic, one cannot ignore the need to continue providing chronically ill patients all the health care they need, in terms of detection, prevention, and treatment. In these unprecedented times, liquid biopsy, more than ever before, may play a relevant role in the adequate management of these frail patients. Methods we performed a deep analysis of the recent international literature published in English on PUBMED in the last six months focused on the impact of SARS-CoV-2 on the management of lung cancer patients, focusing the attention on the role of liquid biopsy. Conclusions COVID-19 pandemic has significantly modified our lives and overall medical practice. In these unprecedented times, liquid biopsy may represent a valid and less time-consuming diagnostic approach than conventional tissue and cytological specimens.
Collapse
Affiliation(s)
- Pasquale Pisapia
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Francesco Pepe
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Valerio Gristina
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | - Maria La Mantia
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| | | | - Gianluca Russo
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Antonino Iaccarino
- Department of Public Health, University of Naples Federico II, Naples, Italy
| | - Antonio Galvano
- Department of Surgical, Oncological and Oral Sciences, University of Palermo, Palermo, Italy
| |
Collapse
|
246
|
Stawski R, Nowak D, Perdas E. Cell-Free DNA: Potential Application in COVID-19 Diagnostics and Management. Viruses 2022; 14:321. [PMID: 35215914 PMCID: PMC8880801 DOI: 10.3390/v14020321] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2021] [Revised: 01/28/2022] [Accepted: 02/01/2022] [Indexed: 12/04/2022] Open
Abstract
WHO has declared COVID-19 as a worldwide, public health emergency. The elderly, pregnant women, and people with associated co-morbidities, including pulmonary disease, heart failure, diabetes, and cancer are the most predisposed population groups to infection. Cell-free DNA is a very commonly applied marker, which is elevated in various pathological conditions. However, it has a much higher sensitivity than standard biochemical markers. cfDNA appears to be an effective marker of COVID-19 complications, and also serves as a marker of certain underlying health conditions and risk factors of severe illness during COVID-19 infection. We aimed to present the possible mechanisms and sources of cfDNA released during moderate and severe infections. Moreover, we attempt to verify how efficiently cfDNA increase could be applied in COVID-19 risk assessment and how it corresponds with epidemiological data.
Collapse
Affiliation(s)
- Robert Stawski
- Department of Clinical Physiology, Medical University of Lodz, 92-215 Lodz, Poland;
| | - Dariusz Nowak
- Department of Clinical Physiology, Medical University of Lodz, 92-215 Lodz, Poland;
| | - Ewelina Perdas
- Department of Biostatistics and Translational Medicine, Medical University of Lodz, 92-215 Lodz, Poland
| |
Collapse
|
247
|
Hermel DJ, Cham J, Spierling Bagsic SR, Hong LK, Costantini CL, Mason JR, Saven A, Sigal DS. An observational study of hospitalized COVID-19 patients with cancer in San Diego county. Future Oncol 2022; 18:719-725. [PMID: 35105156 PMCID: PMC8809375 DOI: 10.2217/fon-2021-1116] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Accepted: 11/23/2021] [Indexed: 11/21/2022] Open
Abstract
Aim: To delineate clinical correlates of COVID-19 infection severity in hospitalized patients with malignancy. Methods: The authors conducted a retrospective review of all hospitalized patients with a hematologic and/or solid tumor malignancy presenting to the authors' institution between 1 March 2020 and 5 January 2021, with a laboratory confirmed diagnosis of COVID-19. Univariate and multivariate logistic regression analyses were used to determine associations between specific severity outcomes and clinical characteristics. Results: Among 2771 hospitalized patients with COVID-19, 246 (8.88%) met inclusion criteria. Patients who were actively receiving treatment had an increased rate of death following admission (odds ratio [OR]: 2.7). After adjusting for significant covariates, the odds ratio increased to 4.4. Patients with cancer involvement of the lungs had a trend toward increased odds of death after adjusting for covariates (OR: 2.3). Conclusions: Among COVID-19 positive hospitalized cancer patients, systemic anti-cancer therapy was associated with significantly increased odds of mortality.
Collapse
Affiliation(s)
- David J Hermel
- Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA
| | - Jason Cham
- Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA
| | | | - Lee K Hong
- Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA
| | | | - James R Mason
- Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA
| | - Alan Saven
- Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA
| | - Darren S Sigal
- Division of Hematology & Oncology, Scripps Clinic, La Jolla, CA 92037, USA
| |
Collapse
|
248
|
Asghar MS, Yasmin F, Babar MS, Bin Zafar MD, Ismail Shah SM, Tahir MJ. Clinical characteristics and outcomes of cancer patients and their hospital course during the COVID-19 pandemic in a developing country. Ann Med Surg (Lond) 2022; 74:103284. [PMID: 35127069 PMCID: PMC8800933 DOI: 10.1016/j.amsu.2022.103284] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2021] [Accepted: 01/22/2022] [Indexed: 11/03/2022] Open
Abstract
In the new Coronavirus Disease 2019 (COVID-19) pandemic, cancer patients are considered a particularly susceptible population. We compared the type and magnitude of COVID-19 clinical manifestations among cancer patients in our center to non-cancer COVID-19 affected patients including 99 patients (28 cancer patients and 71 non-cancer patients). Hepatocellular carcinoma, breast carcinoma, and leukemia were the most common cancers. Diabetes and hypertension were prevalent comorbidities. Dyspnea, cough, fatigue, myalgia and diarrhea were statistically indifferent in both groups. Fatigue was more pronounced in cancer patients [OR: 2.573(1.025–6.460), p = 0.041] along with early onset of bilateral patchy consolidation [HR: 3.127(1.197–5.851), p = 0.032].
Collapse
|
249
|
Gounant V, Ferré VM, Soussi G, Charpentier C, Flament H, Fidouh N, Collin G, Namour C, Assoun S, Bizot A, Brouk Z, Vicaut E, Teixeira L, Descamps D, Zalcman G. Efficacy of Severe Acute Respiratory Syndrome Coronavirus-2 Vaccine in Patients With Thoracic Cancer: A Prospective Study Supporting a Third Dose in Patients With Minimal Serologic Response After Two Vaccine Doses. J Thorac Oncol 2022; 17:239-251. [PMID: 34798306 PMCID: PMC8593625 DOI: 10.1016/j.jtho.2021.10.015] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Revised: 10/10/2021] [Accepted: 10/25/2021] [Indexed: 02/08/2023]
Abstract
INTRODUCTION Coronavirus disease 2019 resulted in a 30% mortality rate in patients with thoracic cancer. Given that patients with cancer were excluded from serum antisevere acute respiratory syndrome coronavirus-2 (SARS-CoV-2) vaccine registration trials, it is still unknown whether they would develop a protective antispike antibody response after vaccination. This prospective vaccine monitoring study primarily aimed to assess humoral responses to the SARS-CoV-2 vaccine in patients with thoracic cancer. METHODS SARS-CoV-2-spike antibodies were measured using the Abbot Architect SARS-CoV-2 immunoglobulin G immunoassay before the first injection of BNT162b2 mRNA vaccine, at week 4, and 2 to 16 weeks after the second vaccine dose administration. The factors associated with antibody response were analyzed. RESULTS Overall, 306 patients, with a median age of 67.0 years (interquartile range: 58-74), were vaccinated. Of these, 283 patients received two vaccine doses at 28-day intervals. After a 6.7-month median follow-up, eight patients (2.6%) contracted proven symptomatic SARS-CoV-2 infection, with rapid favorable evolution. Of the 269 serologic results available beyond day 14 after the second vaccine dose administration, 17 patients (6.3%) were still negative (<50 arbitrary units/mL, whereas 34 (11%) were less than 300 arbitrary units/mL (12.5th percentile). In multivariate analysis, only age (p < 0.01) and long-term corticosteroid treatment (p = 0.01) were significantly associated with a lack of immunization. A total of 30 patients received a third vaccine dose, with only three patients showing persistently negative serology thereafter, whereas the others exhibited clear seroconversion. CONCLUSIONS SARS-CoV2 vaccines were found to be efficient in patients with thoracic cancer, most of them being immunized after two doses. A third shot given to 1% of patients with persistent low antibody titers resulted in an 88% immunization rate.
Collapse
Affiliation(s)
- Valérie Gounant
- Thoracic Oncology Department, Université de Paris, North-Paris Cancer University Institute, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Valentine Marie Ferré
- Virology Department, Université de Paris, INSERM Unité Mixte de Recherche (UMR) 1137 Infection, Antimicrobials, Modelling, Evolution, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Ghassen Soussi
- Thoracic Oncology Department, Université de Paris, North-Paris Cancer University Institute, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Charlotte Charpentier
- Virology Department, Université de Paris, INSERM Unité Mixte de Recherche (UMR) 1137 Infection, Antimicrobials, Modelling, Evolution, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Héloïse Flament
- Hematology, and Immunology Department, Université de Paris, INSERM-U1149, Research Center on Inflammation (CRI) Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Nadhira Fidouh
- Virology Department, Université de Paris, INSERM Unité Mixte de Recherche (UMR) 1137 Infection, Antimicrobials, Modelling, Evolution, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Gilles Collin
- Virology Department, Université de Paris, INSERM Unité Mixte de Recherche (UMR) 1137 Infection, Antimicrobials, Modelling, Evolution, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Céline Namour
- Thoracic Oncology Department, Université de Paris, North-Paris Cancer University Institute, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Sandra Assoun
- Thoracic Oncology Department, Université de Paris, North-Paris Cancer University Institute, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Alexandra Bizot
- Thoracic Oncology Department, Université de Paris, North-Paris Cancer University Institute, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Zohra Brouk
- Thoracic Oncology Department, Université de Paris, North-Paris Cancer University Institute, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Eric Vicaut
- Biostatistics and Clinical Research Department, Université de Paris, Lariboisière Hospital (AP-HP.Nord), Paris, France
| | - Luis Teixeira
- Breast Diseases Centre, North-Paris Cancer University Institute, Université de Paris, INSERM U976 Human Immunology, Pathophysiology, Immunotherapy (HIPI) (Pathophysiology of Breast Cancer Team), Saint-Louis Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Diane Descamps
- Virology Department, Université de Paris, INSERM Unité Mixte de Recherche (UMR) 1137 Infection, Antimicrobials, Modelling, Evolution, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France
| | - Gérard Zalcman
- Thoracic Oncology Department, Université de Paris, North-Paris Cancer University Institute, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France; Institut National de la Santé et de la Recherche Médicale (INSERM), Centre d'Investigation Clinique 1425, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP.Nord), Paris, France; INSERM U830 Cancer, Heterogeneity Plasticity, Curie Institute Research Centre, Paris, France.
| |
Collapse
|
250
|
A definitive prognostication system for patients with thoracic malignancies diagnosed with COVID-19: an update from the TERAVOLT registry. J Thorac Oncol 2022; 17:661-674. [PMID: 35121086 PMCID: PMC8804493 DOI: 10.1016/j.jtho.2021.12.015] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2021] [Revised: 12/16/2021] [Accepted: 12/31/2021] [Indexed: 12/15/2022]
Abstract
INTRODUCTION Patients with thoracic malignancies are at increased risk for mortality from coronavirus disease 2019 (COVID-19), and a large number of intertwined prognostic variables have been identified so far. METHODS Capitalizing data from the Thoracic Cancers International COVID-19 Collaboration (TERAVOLT) registry, a global study created with the aim of describing the impact of COVID-19 in patients with thoracic malignancies, we used a clustering approach, a fast-backward step-down selection procedure, and a tree-based model to screen and optimize a broad panel of demographics and clinical COVID-19 and cancer characteristics. RESULTS As of April 15, 2021, a total of 1491 consecutive eligible patients from 18 countries were included in the analysis. With a mean observation period of 42 days, 361 events were reported with an all-cause case fatality rate of 24.2%. The clustering procedure screened 73 covariates in 13 clusters. A further multivariable logistic regression for the association between clusters and death was performed, resulting in five clusters significantly associated with the outcome. The fast-backward step-down selection procedure then identified the following seven major determinants of death: Eastern Cooperative Oncology Group-performance status (ECOG-PS) (OR = 2.47, 1.87-3.26), neutrophil count (OR = 2.46, 1.76-3.44), serum procalcitonin (OR = 2.37, 1.64-3.43), development of pneumonia (OR = 1.95, 1.48-2.58), C-reactive protein (OR = 1.90, 1.43-2.51), tumor stage at COVID-19 diagnosis (OR = 1.97, 1.46-2.66), and age (OR = 1.71, 1.29-2.26). The receiver operating characteristic analysis for death of the selected model confirmed its diagnostic ability (area under the receiver operating curve = 0.78, 95% confidence interval: 0.75-0.81). The nomogram was able to classify the COVID-19 mortality in an interval ranging from 8% to 90%, and the tree-based model recognized ECOG-PS, neutrophil count, and c-reactive protein as the major determinants of prognosis. CONCLUSIONS From 73 variables analyzed, seven major determinants of death have been identified. Poor ECOG-PS was found to have the strongest association with poor outcome from COVID-19. With our analysis, we provide clinicians with a definitive prognostication system to help determine the risk of mortality for patients with thoracic malignancies and COVID-19.
Collapse
|